T.	NP	T.
[	SYM	[
The	DT	the
role	NN	role
of	IN	of
the	DT	the
human	JJ	human
microbiom	NN	<unknown>
in	IN	in
the	DT	the
pathogenesis	NN	pathogenesis
of	IN	of
rheumatoid	JJ	rheumatoid
arthritis	NN	arthritis
-	:	-
a	DT	a
literature	NN	literature
review	NN	review
]	SYM	]
.	SENT	.
A.	NP	A.
Rheumatoid	NP	<unknown>
arthritis	NN	arthritis
is	VBZ	be
a	DT	a
chronic	JJ	chronic
,	,	,
progressive	JJ	progressive
,	,	,
autoimmune	JJ	autoimmune
disease	NN	disease
with	IN	with
numerous	JJ	numerous
articular	JJ	articular
,	,	,
extra-articular	JJ	<unknown>
and	CC	and
systemic	JJ	systemic
manifestations	NNS	manifestation
.	SENT	.
The	DT	the
cause	NN	cause
of	IN	of
rheumatoid	JJ	rheumatoid
arthritis	NN	arthritis
is	VBZ	be
multifactorial	JJ	multifactorial
including	VVG	include
genetic	JJ	genetic
and	CC	and
environmental	JJ	environmental
factors	NNS	factor
.	SENT	.
Recent	JJ	Recent
advantages	NNS	advantage
in	IN	in
sequencing	VVG	sequence
techniques	NNS	technique
have	VHP	have
allowed	VVN	allow
the	DT	the
deep	JJ	deep
characterization	NN	characterization
of	IN	of
the	DT	the
human	JJ	human
microbiota	NN	<unknown>
.	SENT	.
Available	JJ	available
evidence	NN	evidence
confirms	VVZ	confirm
the	DT	the
existence	NN	existence
of	IN	of
an	DT	an
association	NN	association
between	IN	between
dysbiosis	NN	<unknown>
and	CC	and
rheumatoid	JJ	rheumatoid
arthritis	NN	arthritis
but	CC	but
it	PP	it
still	RB	still
remains	VVZ	remain
unclear	JJ	unclear
whether	IN	whether
alterations	NNS	alteration
in	IN	in
the	DT	the
microbiome	NN	<unknown>
are	VBP	be
a	DT	a
pathogenic	JJ	pathogenic
cause	NN	cause
or	CC	or
an	DT	an
effect	NN	effect
of	IN	of
autoimmune	JJ	autoimmune
disease	NN	disease
.	SENT	.
In	IN	in
patients	NNS	patient
with	IN	with
rheumatoid	JJ	rheumatoid
arthritis	NN	arthritis
the	DT	the
most	RBS	most
supported	VVN	support
association	NN	association
between	IN	between
disease	NN	disease
and	CC	and
microbiota	NN	<unknown>
is	VBZ	be
with	IN	with
the	DT	the
oral	JJ	oral
dysbiosis	NN	<unknown>
usually	RB	usually
observed	VVD	observe
in	IN	in
patients	NNS	patient
with	IN	with
periodontitis	NN	<unknown>
.	SENT	.
Given	VVN	give
the	DT	the
strong	JJ	strong
variability	NN	variability
and	CC	and
abundance	NN	abundance
of	IN	of
microbes	NNS	microbe
living	VVG	live
in	IN	in
close	JJ	close
relation	NN	relation
with	IN	with
human	JJ	human
host	NN	host
,	,	,
it	PP	it
becomes	VVZ	become
a	DT	a
difficult	JJ	difficult
task	NN	task
to	TO	to
define	VV	define
what	WP	what
should	MD	should
be	VB	be
considered	VVN	consider
the	DT	the
favorable	JJ	favorable
microbiome	NN	<unknown>
.	SENT	.
There	EX	there
is	VBZ	be
need	NN	need
for	IN	for
broader	JJR	broad
studies	NNS	study
to	TO	to
establish	VV	establish
how	WRB	how
the	DT	the
human	JJ	human
microbiome	NN	<unknown>
contributes	VVZ	contribute
to	TO	to
disease	NN	disease
susceptibility	NN	susceptibility
,	,	,
and	CC	and
to	TO	to
characterize	VV	characterize
the	DT	the
role	NN	role
of	IN	of
microbial	JJ	microbial
diversity	NN	diversity
in	IN	in
the	DT	the
pathogenesis	NN	pathogenesis
of	IN	of
rheumatoid	JJ	rheumatoid
arthritis	NN	arthritis
,	,	,
disease	NN	disease
manifestation	NN	manifestation
,	,	,
and	CC	and
progression	NN	progression
.	SENT	.
The	DT	the
identification	NN	identification
of	IN	of
dysbiosis	NN	<unknown>
specific	JJ	specific
for	IN	for
rheumatoid	JJ	rheumatoid
arthritis	NN	arthritis
and	CC	and
the	DT	the
understanding	NN	understanding
of	IN	of
the	DT	the
dynamic	JJ	dynamic
interaction	NN	interaction
between	IN	between
microbiota	NN	<unknown>
and	CC	and
their	PP$	their
host	NN	host
may	MD	may
help	VV	help
in	IN	in
establishing	VVG	establish
an	DT	an
individualized	VVN	individualize
management	NN	management
for	IN	for
each	DT	each
patient	NN	patient
with	IN	with
rheumatoid	JJ	rheumatoid
arthritis	NN	arthritis
,	,	,
and	CC	and
achieve	VV	achieve
a	DT	a
better	JJR	good
efficacy	NN	efficacy
of	IN	of
the	DT	the
therapy	NN	therapy
.	SENT	.
T.	NP	T.
Dimethyl	NP	<unknown>
fumarate	NN	<unknown>
inhibits	VVZ	inhibit
osteoclasts	NNS	osteoclast
via	IN	via
attenuation	NN	attenuation
of	IN	of
reactive	JJ	reactive
oxygen	NN	oxygen
species	NNS	specie
signalling	VVG	signal
by	IN	by
augmented	JJ	augmented
antioxidation	NN	<unknown>
.	SENT	.
A.	NP	A.
Bone	NP	Bone
destructive	JJ	destructive
diseases	NNS	disease
are	VBP	be
common	JJ	common
worldwide	JJ	worldwide
and	CC	and
are	VBP	be
caused	VVN	cause
by	IN	by
dysregulation	NN	<unknown>
of	IN	of
osteoclast	NN	osteoclast
formation	NN	formation
and	CC	and
activation	NN	activation
.	SENT	.
During	IN	during
osteoclastogenesis	NN	<unknown>
,	,	,
reactive	JJ	reactive
oxygen	NN	oxygen
species	NNS	specie
(	(	(
ROS	NP	Ros
)	)	)
play	VVP	play
a	DT	a
role	NN	role
in	IN	in
the	DT	the
intracellular	JJ	intracellular
signalling	VVG	signal
triggered	VVN	trigger
by	IN	by
receptor	NN	receptor
activator	NN	activator
of	IN	of
nuclear	JJ	nuclear
factor-κB	NN	<unknown>
ligand	NN	ligand
(	(	(
RANKL	NP	<unknown>
)	)	)
stimulation	NN	stimulation
.	SENT	.
Previously	RB	previously
,	,	,
we	PP	we
demonstrated	VVD	demonstrate
that	DT	that
induction	NN	induction
of	IN	of
antioxidant	NN	antioxidant
enzymes	NNS	enzyme
by	IN	by
Nrf2	JJ	<unknown>
activation	NN	activation
using	VVG	use
Nrf2-gene	NP	<unknown>
transfer	NN	transfer
,	,	,
an	DT	an
ETGE-peptide	NN	<unknown>
or	CC	or
polyphenols	NNS	<unknown>
,	,	,
successfully	RB	successfully
ameliorated	VVN	ameliorate
RANKL-dependent	NP	<unknown>
osteoclastogenesis	NN	<unknown>
.	SENT	.
Dimethyl	NP	<unknown>
fumarate	NNS	<unknown>
(	(	(
DMF	NP	<unknown>
)	)	)
has	VHZ	have
been	VBN	be
shown	VVN	show
to	TO	to
activate	VV	activate
Nrf2	NP	<unknown>
signalling	VVG	signal
and	CC	and
has	VHZ	have
been	VBN	be
lately	RB	lately
used	VVN	use
in	IN	in
clinical	JJ	clinical
trials	NNS	trial
for	IN	for
neurodegenerative	JJ	<unknown>
diseases	NNS	disease
.	SENT	.
In	IN	in
this	DT	this
study	NN	study
,	,	,
we	PP	we
hypothesized	VVD	hypothesize
that	IN/that	that
Nrf2	JJ	<unknown>
activation	NN	activation
by	IN	by
DMF	NP	<unknown>
would	MD	would
inhibit	VV	inhibit
osteoclastogenesis	NN	<unknown>
and	CC	and
bone	NN	bone
destruction	NN	destruction
via	IN	via
attenuation	NN	attenuation
of	IN	of
intracellular	JJ	intracellular
ROS	NP	Ros
signalling	VVG	signal
through	IN	through
antioxidant	NN	antioxidant
mechanisms	NNS	mechanism
.	SENT	.
RAW	JJ	raw
264.7	CD	@card@
cells	NNS	cell
were	VBD	be
used	VVN	use
as	IN	as
osteoclast	NN	osteoclast
progenitor	NN	progenitor
cells	NNS	cell
.	SENT	.
We	PP	we
found	VVD	find
that	IN/that	that
DMF	NP	<unknown>
induced	VVD	induce
Nrf2	JJ	<unknown>
translocation	NN	translocation
to	TO	to
the	DT	the
nucleus	NN	nucleus
,	,	,
augmented	JJ	augmented
Nrf2	JJ	<unknown>
promoter-luciferase	NN	<unknown>
reporter	NN	reporter
activity	NN	activity
and	CC	and
increased	VVN	increase
antioxidant	NN	antioxidant
enzyme	NN	enzyme
expression	NN	expression
.	SENT	.
Using	VVG	use
flow	NN	flow
cytometry	NN	<unknown>
,	,	,
we	PP	we
found	VVD	find
that	IN/that	that
DMF	NP	<unknown>
attenuated	VVN	attenuate
RANKL-mediated	JJ	<unknown>
intracellular	JJ	intracellular
ROS	NP	Ros
generation	NN	generation
,	,	,
which	WDT	which
resulted	VVD	result
in	IN	in
the	DT	the
inhibition	NN	inhibition
of	IN	of
RANKL-mediated	JJ	<unknown>
osteoclastogenesis	NN	<unknown>
.	SENT	.
Local	JJ	local
DMF	NP	<unknown>
injection	NN	injection
into	IN	into
the	DT	the
calvaria	NN	calvaria
of	IN	of
male	JJ	male
BALB/c	NP	<unknown>
mice	NNS	mouse
resulted	VVD	result
in	IN	in
attenuated	JJ	attenuated
bone	NN	bone
destruction	NN	destruction
in	IN	in
lipopolysaccharide-treated	JJ	<unknown>
mice	NNS	mouse
.	SENT	.
In	IN	in
conclusion	NN	conclusion
,	,	,
we	PP	we
demonstrated	VVD	demonstrate
in	IN	in
a	DT	a
preclinical	JJ	preclinical
setting	NN	setting
that	IN/that	that
DMF	NP	<unknown>
inhibited	VVD	inhibit
RANKL-mediated	JJ	<unknown>
osteoclastogenesis	NN	<unknown>
and	CC	and
bone	NN	bone
destruction	NN	destruction
via	IN	via
induction	NN	induction
of	IN	of
Nrf2-mediated	JJ	<unknown>
transcription	NN	transcription
of	IN	of
antioxidant	NN	antioxidant
genes	NNS	gene
and	CC	and
consequent	JJ	consequent
decrease	NN	decrease
in	IN	in
intracellular	JJ	intracellular
ROS	NP	Ros
levels	NNS	level
.	SENT	.
Our	PP$	our
results	NNS	result
suggest	VVP	suggest
that	IN/that	that
DMF	NP	<unknown>
may	MD	may
be	VB	be
a	DT	a
promising	JJ	promising
inhibitor	NN	inhibitor
of	IN	of
bone	NN	bone
destruction	NN	destruction
in	IN	in
diseases	NNS	disease
like	IN	like
periodontitis	NN	<unknown>
,	,	,
rheumatoid	JJ	rheumatoid
arthritis	NN	arthritis
and	CC	and
osteoporosis	NN	osteoporosis
.	SENT	.
T.	NP	T.
Targeting	NP	<unknown>
of	IN	of
circulating	VVG	circulate
Th17	JJ	<unknown>
cells	NNS	cell
by	IN	by
β-D-mannuronic	JJ	<unknown>
acid	NN	acid
(	(	(
M2000	NP	<unknown>
)	)	)
as	IN	as
a	DT	a
novel	JJ	novel
medication	NN	medication
in	IN	in
patients	NNS	patient
with	IN	with
rheumatoid	JJ	rheumatoid
arthritis	NN	arthritis
.	SENT	.
A.	NP	A.
This	DT	this
study	NN	study
aimed	VVN	aim
at	IN	at
investigating	VVG	investigate
the	DT	the
inhibitory	JJ	inhibitory
effect	NN	effect
of	IN	of
β-D-mannuronic	JJ	<unknown>
acid	NN	acid
(	(	(
M2000	NP	<unknown>
)	)	)
on	IN	on
the	DT	the
Th17	JJ	<unknown>
circulating	VVG	circulate
levels	NNS	level
and	CC	and
IL-17	JJ	<unknown>
a	DT	a
related	JJ	related
cytokine	NN	<unknown>
in	IN	in
rheumatoid	JJ	rheumatoid
arthritis	NN	arthritis
(	(	(
RA	NP	RA
)	)	)
patients.The	NN	<unknown>
study	NN	study
included	VVD	include
27	CD	@card@
patients	NNS	patient
with	IN	with
RA	NP	RA
who	WP	who
had	VHD	have
failed	VVN	fail
response	NN	response
to	TO	to
treatment	NN	treatment
.	SENT	.
All	DT	all
patients	NNS	patient
were	VBD	be
treated	VVN	treat
orally	RB	orally
by	IN	by
M2000	NP	<unknown>
at	IN	at
a	DT	a
dose	NN	dose
of	IN	of
500	CD	@card@
mg	NN	mg
twice	RB	twice
daily	JJ	daily
for	IN	for
12	CD	@card@
weeks	NNS	week
(	(	(
Clinical	JJ	clinical
trial	NN	trial
identifier	NN	identifier
:	:	:
IRCT2014011213739N2	NP	<unknown>
)	)	)
.	SENT	.
The	DT	the
patients	NNS	patient
based	VVN	base
on	IN	on
anti-tumor	NP	anti-tumor
necrosis	NN	necrosis
factor	NN	factor
alpha	NN	alpha
(	(	(
TNFα	NP	<unknown>
)	)	)
blocker	NN	blocker
treatment	NN	treatment
were	VBD	be
classified	VVN	classify
into	IN	into
two	CD	two
groups	NNS	group
(	(	(
conventional	JJ	conventional
group	NN	group
and	CC	and
etanercept	NN	<unknown>
group	NN	group
)	)	)
.	SENT	.
They	PP	they
were	VBD	be
then	RB	then
allowed	VVN	allow
to	TO	to
continue	VV	continue
their	PP$	their
treatment	NN	treatment
excluding	VVG	exclude
non-steroidal	NN	non-steroidal
anti-inflammatory	JJ	anti-inflammatory
drugs	NNS	drug
(	(	(
NSAIDs	NP	<unknown>
)	)	)
.	SENT	.
The	DT	the
frequency	NN	frequency
of	IN	of
circulating	VVG	circulate
Th17	JJ	<unknown>
cells	NNS	cell
and	CC	and
IL-17	JJ	<unknown>
serum	NN	serum
level	NN	level
were	VBD	be
determined	VVN	determine
before	IN	before
and	CC	and
12	CD	@card@
weeks	NNS	week
after	IN	after
M2000	NP	<unknown>
therapy	NN	therapy
and	CC	and
were	VBD	be
compared	VVN	compare
to	TO	to
the	DT	the
healthy	JJ	healthy
controls	NNS	control
by	IN	by
using	VVG	use
flow	NN	flow
cytometry	NN	<unknown>
analysis	NN	analysis
and	CC	and
ELISA	NP	Elisa
method	NN	method
,	,	,
respectively.At	NN	<unknown>
baseline	NN	baseline
,	,	,
higher	RBR	higher
circulating	VVG	circulate
Th17	JJ	<unknown>
and	CC	and
IL-17	JJ	<unknown>
serum	NN	serum
levels	NNS	level
were	VBD	be
significantly	RB	significantly
observed	VVN	observe
in	IN	in
both	DT	both
groups	NNS	group
of	IN	of
RA	NP	RA
patients	NNS	patient
than	IN	than
in	IN	in
the	DT	the
healthy	JJ	healthy
controls	NNS	control
(	(	(
all	DT	all
P	NN	P
&lt	NN	<unknown>
;	:	;
0.001	LS	@card@
)	)	)
.	SENT	.
The	DT	the
frequency	NN	frequency
of	IN	of
Th17	JJ	<unknown>
cells	NNS	cell
significantly	RB	significantly
decreased	VVD	decrease
in	IN	in
the	DT	the
conventional	JJ	conventional
group	NN	group
as	IN	as
well	RB	well
as	RB	as
in	IN	in
the	DT	the
etanercept	NN	<unknown>
group	NN	group
after	IN	after
M2000	NP	<unknown>
therapy	NN	therapy
but	CC	but
the	DT	the
level	NN	level
of	IN	of
reduction	NN	reduction
was	VBD	be
higher	JJR	high
in	IN	in
the	DT	the
conventional	JJ	conventional
group	NN	group
compared	VVN	compare
to	TO	to
the	DT	the
etanercept	NN	<unknown>
group	NN	group
(	(	(
P	NN	P
&lt	NN	<unknown>
;	:	;
0.03	CD	@card@
and	CC	and
P	NN	P
&lt	NN	<unknown>
;	:	;
0.04	CD	@card@
,	,	,
respectively	RB	respectively
)	)	)
.	SENT	.
The	DT	the
IL-17	JJ	<unknown>
serum	NN	serum
level	NN	level
significantly	RB	significantly
decreased	VVD	decrease
in	IN	in
both	DT	both
groups	NNS	group
after	IN	after
M2000	NP	<unknown>
therapy	NN	therapy
(	(	(
P	NN	P
&lt	NN	<unknown>
;	:	;
0.01	CD	@card@
and	CC	and
P	NN	P
&lt	NN	<unknown>
;	:	;
0.02	CD	@card@
,	,	,
respectively	RB	respectively
)	)	)
.	SENT	.
Furthermore	RB	furthermore
,	,	,
the	DT	the
frequency	NN	frequency
of	IN	of
Th17	JJ	<unknown>
cells	NNS	cell
was	VBD	be
positively	RB	positively
correlated	VVN	correlate
with	IN	with
Disease	NP	Disease
Activity	NP	Activity
Score	NP	Score
(	(	(
DAS28	NP	<unknown>
)	)	)
(	(	(
r	LS	r
=	SYM	=
0.34	CD	@card@
,	,	,
P	NN	P
=	SYM	=
0.02).M2000	NN	<unknown>
shows	VVZ	show
the	DT	the
inhibitory	JJ	inhibitory
effect	NN	effect
on	IN	on
the	DT	the
frequency	NN	frequency
of	IN	of
circulating	VVG	circulate
Th17	JJ	<unknown>
cells	NNS	cell
as	IN	as
well	RB	well
as	RB	as
in	IN	in
the	DT	the
production	NN	production
of	IN	of
IL-17	JJ	<unknown>
in	IN	in
RA	NP	RA
patients	NNS	patient
.	SENT	.
T.	NP	T.
Diverse	NP	<unknown>
patterns	NNS	pattern
of	IN	of
anti-TNF-α-induced	JJ	<unknown>
lupus	NN	lupus
:	:	:
case	NN	case
series	NN	series
and	CC	and
review	NN	review
of	IN	of
the	DT	the
literature	NN	literature
.	SENT	.
A.	NP	A.
The	DT	the
induction	NN	induction
of	IN	of
autoantibodies	NNS	autoantibody
is	VBZ	be
common	JJ	common
following	VVG	follow
therapy	NN	therapy
with	IN	with
anti-TNF-α	JJ	<unknown>
agents	NNS	agent
.	SENT	.
However	RB	however
,	,	,
anti-TNF-α-induced	JJ	<unknown>
lupus	NN	lupus
(	(	(
ATIL	NP	<unknown>
)	)	)
is	VBZ	be
rare	JJ	rare
.	SENT	.
We	PP	we
assessed	VVD	assess
the	DT	the
clinical	JJ	clinical
characteristics	NNS	characteristic
of	IN	of
three	CD	three
patients	NNS	patient
with	IN	with
inflammatory	JJ	inflammatory
bowel	NN	bowel
disease	NN	disease
(	(	(
IBD	JJ	<unknown>
)	)	)
who	WP	who
were	VBD	be
treated	VVN	treat
with	IN	with
infliximab	NN	<unknown>
and	CC	and
developed	VVN	develop
distinct	JJ	distinct
subsets	NNS	subset
of	IN	of
ATIL	NP	<unknown>
.	SENT	.
Also	RB	also
,	,	,
we	PP	we
searched	VVD	search
for	IN	for
similar	JJ	similar
cases	NNS	case
in	IN	in
the	DT	the
published	VVN	publish
literature	NN	literature
.	SENT	.
We	PP	we
describe	VVP	describe
three	CD	three
patients	NNS	patient
with	IN	with
ATIL	NP	<unknown>
.	SENT	.
The	DT	the
first	JJ	first
patient	NN	patient
had	VHD	have
a	DT	a
classical	JJ	classical
drug-induced	JJ	drug-induced
lupus	NN	lupus
(	(	(
DIL	NP	<unknown>
)	)	)
presented	VVD	present
by	IN	by
thrombocytopenia	NN	<unknown>
that	IN/that	that
resolved	VVN	resolve
after	IN	after
infliximab	NN	<unknown>
discontinuation	NN	discontinuation
.	SENT	.
The	DT	the
second	JJ	second
case	NN	case
experienced	VVD	experience
symmetric	JJ	symmetric
polyarthritis	NN	<unknown>
of	IN	of
14	CD	@card@
joints	NNS	joint
in	IN	in
rheumatoid	JJ	rheumatoid
arthritis	NN	arthritis
(	(	(
RA)-like	JJ	<unknown>
distribution	NN	distribution
accompanied	VVN	accompany
by	IN	by
lymphopenia	NN	<unknown>
.	SENT	.
The	DT	the
third	NN	third
one	PP	one
had	VHD	have
a	DT	a
severe	JJ	severe
serositis	NN	<unknown>
including	VVG	include
ascites	NN	ascites
and	CC	and
pleural	JJ	pleural
and	CC	and
pericardial	JJ	pericardial
effusions	NNS	effusion
along	IN	along
with	IN	with
pancytopenia	NN	<unknown>
.	SENT	.
In	IN	in
this	DT	this
patient	NN	patient
,	,	,
ATIL	NP	<unknown>
coexisted	VVD	coexist
with	IN	with
anti-TNF-α-induced	JJ	<unknown>
hepatitis	NN	hepatitis
.	SENT	.
The	DT	the
second	JJ	second
and	CC	and
third	JJ	third
patients	NNS	patient
met	VVD	meet
the	DT	the
American	NP	American
College	NP	College
of	IN	of
Rheumatology	NP	<unknown>
classification	NN	classification
criteria	NNS	criterion
for	IN	for
SLE	NP	<unknown>
.	SENT	.
Nevertheless	RB	nevertheless
,	,	,
all	DT	all
three	CD	three
cases	NNS	case
exhibited	VVN	exhibit
ANA	NP	Ana
and	CC	and
anti-dsDNA	NP	<unknown>
positivity	NN	<unknown>
,	,	,
and	CC	and
only	RB	only
the	DT	the
second	JJ	second
patient	NN	patient
had	VHD	have
anticardiolipin	NN	<unknown>
(	(	(
aCL	NP	<unknown>
IgG	NP	IgG
)	)	)
and	CC	and
anti-histone	NN	<unknown>
antibodies	NNS	antibody
.	SENT	.
The	DT	the
coexistence	NN	coexistence
of	IN	of
both	DT	both
lupus-like	JJ	<unknown>
syndrome	NN	syndrome
and	CC	and
hepatitis	NN	hepatitis
following	VVG	follow
anti-TNF-α	JJ	<unknown>
therapy	NN	therapy
in	IN	in
the	DT	the
same	JJ	same
patient	NN	patient
is	VBZ	be
very	RB	very
rare	JJ	rare
,	,	,
and	CC	and
to	TO	to
the	DT	the
best	JJS	good
of	IN	of
our	PP$	our
knowledge	NN	knowledge
,	,	,
only	RB	only
four	CD	four
such	JJ	such
case	NN	case
reports	NNS	report
are	VBP	be
mentioned	VVN	mention
in	IN	in
literature	NN	literature
.	SENT	.
Patients	NNS	patient
with	IN	with
mild	JJ	mild
ATIL	NP	<unknown>
may	MD	may
tolerate	VV	tolerate
another	DT	another
anti-TNF-α	JJ	<unknown>
agent	NN	agent
without	IN	without
recurrence	NN	recurrence
of	IN	of
the	DT	the
disease	NN	disease
.	SENT	.
Rheumatologists	NNS	<unknown>
should	MD	should
be	VB	be
aware	JJ	aware
of	IN	of
the	DT	the
distinct	JJ	distinct
clinical	JJ	clinical
presentations	NNS	presentation
of	IN	of
ATIL	NP	<unknown>
and	CC	and
its	PP$	its
coexistence	NN	coexistence
with	IN	with
other	JJ	other
rare	JJ	rare
anti-TNF-alpha	NN	<unknown>
complications	NNS	complication
such	JJ	such
as	IN	as
hepatitis	NP	hepatitis
.	SENT	.
T.	NP	T.
Prevalence	NP	<unknown>
of	IN	of
depression	NN	depression
and	CC	and
anxiety	NN	anxiety
in	IN	in
rheumatoid	JJ	rheumatoid
arthritis	NN	arthritis
patients	NNS	patient
and	CC	and
their	PP$	their
associations	NNS	association
with	IN	with
serum	NN	serum
vitamin	NN	vitamin
D	NP	D
level	NN	level
.	SENT	.
A.	NP	A.
Vitamin	NP	<unknown>
D	NP	D
deficiency	NN	deficiency
may	MD	may
be	VB	be
associated	VVN	associate
with	IN	with
depression	NN	depression
in	IN	in
the	DT	the
general	JJ	general
population	NN	population
.	SENT	.
This	DT	this
study	NN	study
aimed	VVN	aim
to	TO	to
describe	VV	describe
the	DT	the
prevalence	NN	prevalence
of	IN	of
depression	NN	depression
and	CC	and
anxiety	NN	anxiety
in	IN	in
rheumatoid	JJ	rheumatoid
arthritis	NN	arthritis
(	(	(
RA	NP	RA
)	)	)
patients	NNS	patient
from	IN	from
Northwestern	NP	Northwestern
China	NP	China
and	CC	and
identify	VV	identify
associations	NNS	association
of	IN	of
Hamilton	NP	Hamilton
Depression	NP	Depression
Scale	NP	Scale
(	(	(
HAMD	NP	<unknown>
)	)	)
and	CC	and
Hamilton	NP	Hamilton
Anxiety	NP	<unknown>
Scale	NP	Scale
(	(	(
HAMA	NP	Hama
)	)	)
scores	NNS	score
with	IN	with
serum	NN	serum
vitamin	NN	vitamin
D	NP	D
level	NN	level
in	IN	in
these	DT	these
patients	NNS	patient
.	SENT	.
We	PP	we
recruited	VVD	recruit
161	CD	@card@
RA	NP	RA
patients	NNS	patient
inform	VV	inform
the	DT	the
First	NP	First
Affiliated	NP	Affiliated
Hospital	NP	Hospital
of	IN	of
Xi'an	NP	Xi'an
Jiaotong	NP	<unknown>
University	NP	University
during	IN	during
Nov.	NP	Nov.
2016	CD	@card@
to	TO	to
Feb.	NP	Feb.
2017.	CD	@ord@
All	NP	All
patients	NNS	patient
completed	VVD	complete
a	DT	a
survey	NN	survey
including	VVG	include
HAMD	NP	<unknown>
and	CC	and
HAMA	NP	Hama
scales	NNS	scale
.	SENT	.
RA	NP	RA
activity	NN	activity
(	(	(
DAS28	NP	<unknown>
)	)	)
was	VBD	be
scored	VVN	score
by	IN	by
a	DT	a
rheumatologist	NN	rheumatologist
,	,	,
and	CC	and
serum	NN	serum
25-OH-D3	JJ	<unknown>
levels	NNS	level
were	VBD	be
measured	VVN	measure
by	IN	by
electrochemiluminescence	NN	<unknown>
immunoassay	NN	immunoassay
.	SENT	.
The	DT	the
data	NNS	datum
were	VBD	be
analyzed	VVN	analyze
using	VVG	use
the	DT	the
SPSS16.0	NN	<unknown>
based	VVN	base
on	IN	on
"	``	"
possible	JJ	possible
and	CC	and
probable	JJ	probable
"	''	"
cut	NN	cut
points	NNS	point
for	IN	for
HAMD	NP	<unknown>
and	CC	and
HAMA	NP	Hama
.	SENT	.
About	IN	about
62	CD	@card@
and	CC	and
60	CD	@card@
%	NN	%
of	IN	of
patients	NNS	patient
had	VHD	have
some	DT	some
degrees	NNS	degree
of	IN	of
depression	NN	depression
and	CC	and
anxiety	NN	anxiety
,	,	,
respectively	RB	respectively
.	SENT	.
The	DT	the
mean	NN	mean
of	IN	of
serum	NN	serum
25-OH-D3	JJ	<unknown>
levels	NNS	level
in	IN	in
RA	NP	RA
patients	NNS	patient
with	IN	with
depression	NN	depression
was	VBD	be
15.24	CD	@card@
±	SYM	±
8.78	CD	@card@
ng/mL	NNS	<unknown>
,	,	,
which	WDT	which
was	VBD	be
significantly	RB	significantly
lower	JJR	low
than	IN	than
those	DT	those
without	IN	without
depression	NN	depression
(	(	(
24.68	CD	@card@
±	SYM	±
10.98	CD	@card@
ng/mL	NNS	<unknown>
,	,	,
p	NN	p
=	SYM	=
0.009	CD	@card@
)	)	)
.	SENT	.
Despite	IN	despite
negative	JJ	negative
correlations	NNS	correlation
between	IN	between
serum	NN	serum
25-OH-D3	JJ	<unknown>
level	NN	level
and	CC	and
the	DT	the
score	NN	score
of	IN	of
HAMD	NP	<unknown>
(	(	(
r	NN	r
=	SYM	=
-	:	-
0.520	CD	@card@
,	,	,
p	NN	p
&lt	NN	<unknown>
;	:	;
0.001	LS	@card@
)	)	)
or	CC	or
HAMA	NP	Hama
(	(	(
r	NN	r
=	SYM	=
-	:	-
0.469	CD	@card@
,	,	,
p	NN	p
&lt	NN	<unknown>
;	:	;
0.001	LS	@card@
)	)	)
,	,	,
there	EX	there
was	VBD	be
a	DT	a
positive	JJ	positive
correlations	NNS	correlation
between	IN	between
DAS28and	NP	<unknown>
the	DT	the
score	NN	score
of	IN	of
HAMD	NP	<unknown>
(	(	(
r	NN	r
=	SYM	=
0.459	CD	@card@
,	,	,
p	NN	p
=	SYM	=
0.001	CD	@card@
)	)	)
or	CC	or
HAMA	NP	Hama
(	(	(
r	NN	r
=	SYM	=
0.486	CD	@card@
,	,	,
p	NN	p
&lt	NN	<unknown>
;	:	;
0.001	LS	@card@
)	)	)
.	SENT	.
The	DT	the
multivariate	JJ	multivariate
logistic	JJ	logistic
regression	NN	regression
showed	VVD	show
that	IN/that	that
disease	NN	disease
duration	NN	duration
,	,	,
serum	NN	serum
25-OH-D3	JJ	<unknown>
level	NN	level
,	,	,
and	CC	and
treatment	NN	treatment
of	IN	of
tumor	NN	tumor
necrosis	NN	necrosis
factor	NN	factor
inhibitor	NN	inhibitor
were	VBD	be
associated	VVN	associate
with	IN	with
depression/anxiety	NN	<unknown>
in	IN	in
RA	NP	RA
patients	NNS	patient
.	SENT	.
Our	PP$	our
study	NN	study
shows	VVZ	show
a	DT	a
high	JJ	high
prevalence	NN	prevalence
of	IN	of
depression	NN	depression
and	CC	and
anxiety	NN	anxiety
in	IN	in
RA	NP	RA
patients	NNS	patient
from	IN	from
Northwestern	NP	Northwestern
China	NP	China
.	SENT	.
Both	DT	both
disease	NN	disease
activity	NN	activity
of	IN	of
RA	NP	RA
and	CC	and
low	JJ	low
serum	NN	serum
25-OH-D3	JJ	<unknown>
level	NN	level
are	VBP	be
associated	VVN	associate
with	IN	with
the	DT	the
severity	NN	severity
of	IN	of
depression	NN	depression
and	CC	and
anxiety	NN	anxiety
.	SENT	.
It	PP	it
is	VBZ	be
imperative	JJ	imperative
for	IN	for
clinicians	NNS	clinician
to	TO	to
screen	VV	screen
hypovitaminosis	NN	<unknown>
of	IN	of
vitamin	NN	vitamin
D	NN	D
and	CC	and
depression/anxiety	NN	<unknown>
in	IN	in
RA	NP	RA
patients	NNS	patient
.	SENT	.
T.	NP	T.
The	DT	the
role	NN	role
of	IN	of
microalbuminuria	NN	<unknown>
as	IN	as
a	DT	a
predictor	NN	predictor
of	IN	of
subclinical	JJ	subclinical
cardiovascular	JJ	cardiovascular
events	NNS	event
in	IN	in
rheumatoid	JJ	rheumatoid
arthritis	NN	arthritis
patients	NNS	patient
and	CC	and
its	PP$	its
relation	NN	relation
to	TO	to
disease	NN	disease
activity	NN	activity
.	SENT	.
A.	NP	A.
Rheumatoid	NP	<unknown>
arthritis	NN	arthritis
(	(	(
RA	NP	RA
)	)	)
is	VBZ	be
a	DT	a
chronic	JJ	chronic
inflammatory	JJ	inflammatory
autoimmune	JJ	autoimmune
disease	NN	disease
that	WDT	that
affects	VVZ	affect
many	JJ	many
body	NN	body
tissues	NNS	tissue
and	CC	and
leads	VVZ	lead
to	TO	to
major	JJ	major
morbidity	NN	morbidity
and	CC	and
mortality	NN	mortality
.	SENT	.
Renal	JJ	renal
disease	NN	disease
in	IN	in
RA	NP	RA
is	VBZ	be
clinically	RB	clinically
important	JJ	important
because	IN	because
it	PP	it
restricts	VVZ	restrict
the	DT	the
management	NN	management
of	IN	of
primary	JJ	primary
disease	NN	disease
and	CC	and
increases	NNS	increase
mortality	NN	mortality
.	SENT	.
The	DT	the
objectives	NNS	objective
of	IN	of
this	DT	this
study	NN	study
are	VBP	be
to	TO	to
(	(	(
1	LS	1
)	)	)
investigate	VV	investigate
the	DT	the
difference	NN	difference
between	IN	between
RA	NP	RA
patients	NNS	patient
with	IN	with
and	CC	and
without	IN	without
microalbuminuria	NN	<unknown>
(	(	(
MAU	NP	Mau
)	)	)
and	CC	and
(	(	(
2	LS	2
)	)	)
find	VV	find
out	RP	out
the	DT	the
relation	NN	relation
between	IN	between
MAU	NP	Mau
and	CC	and
disease	NN	disease
activity	NN	activity
as	RB	as
well	RB	well
as	IN	as
subclinical	JJ	subclinical
cardiovascular	JJ	cardiovascular
effects	NNS	effect
.	SENT	.
Ninety	CD	ninety
RA	NP	RA
patients	NNS	patient
were	VBD	be
divided	VVN	divide
into	IN	into
two	CD	two
groups	NNS	group
according	VVG	accord
to	TO	to
the	DT	the
presence	NN	presence
of	IN	of
MAU	NP	Mau
,	,	,
in	IN	in
addition	NN	addition
to	TO	to
30	CD	@card@
healthy	JJ	healthy
volunteers	NNS	volunteer
.	SENT	.
ESR	NP	<unknown>
,	,	,
hs-CRP	NP	<unknown>
,	,	,
RF	NP	RF
,	,	,
lipid	NN	lipid
profile	NN	profile
,	,	,
urinary	JJ	urinary
microalbumin	NN	<unknown>
,	,	,
GFR	NP	<unknown>
,	,	,
renal	JJ	renal
function	NN	function
tests	NNS	test
,	,	,
carotid	JJ	carotid
intima	NN	intima
media	NNS	medium
thickness	NN	thickness
(	(	(
cIMT	NN	<unknown>
)	)	)
,	,	,
flow-mediated	JJ	<unknown>
dilatation	NN	<unknown>
of	IN	of
the	DT	the
brachial	JJ	brachial
artery	NN	artery
(	(	(
FMD	NP	<unknown>
)	)	)
,	,	,
ECG	NP	<unknown>
,	,	,
and	CC	and
echocardiographic	JJ	<unknown>
examination	NN	examination
were	VBD	be
performed	VVN	perform
for	IN	for
patients	NNS	patient
and	CC	and
controls	NNS	control
.	SENT	.
MAU	NP	Mau
positive	JJ	positive
RA	NP	RA
patients	NNS	patient
revealed	VVD	reveal
significantly	RB	significantly
higher	JJR	high
lipid	NN	lipid
profile	NN	profile
,	,	,
ESR	NP	<unknown>
,	,	,
hs-CRP	NP	<unknown>
,	,	,
DAS	NP	das
28	CD	@card@
,	,	,
cIMT	NN	<unknown>
,	,	,
and	CC	and
lower	JJR	low
FMD	NN	<unknown>
as	RB	as
well	RB	well
as	IN	as
ECG	NP	<unknown>
and	CC	and
echocardiographic	JJ	<unknown>
abnormalities	NNS	abnormality
compared	VVN	compare
to	TO	to
MAU	NP	Mau
negative	JJ	negative
RA	NP	RA
patients	NNS	patient
.	SENT	.
Moreover	RB	moreover
,	,	,
there	EX	there
was	VBD	be
significant	JJ	significant
positive	JJ	positive
correlation	NN	correlation
between	IN	between
MAU	NP	Mau
and	CC	and
DAS28	NP	<unknown>
,	,	,
hs-CRP	NP	<unknown>
,	,	,
LDL	NP	LDL
,	,	,
cIMT	NN	<unknown>
as	IN	as
well	RB	well
as	IN	as
negative	JJ	negative
correlation	NN	correlation
with	IN	with
FMD	JJ	<unknown>
%	NN	%
.	SENT	.
In	IN	in
our	PP$	our
study	NN	study
,	,	,
all	DT	all
RA	NP	RA
patients	NNS	patient
with	IN	with
MAU	NP	Mau
had	VHD	have
a	DT	a
normal	JJ	normal
serum	NN	serum
creatinine	NN	creatinine
concentration	NN	concentration
and	CC	and
gave	VVD	give
a	DT	a
negative	JJ	negative
result	NN	result
with	IN	with
Albustix	NP	<unknown>
.	SENT	.
MAU	NP	Mau
is	VBZ	be
significantly	RB	significantly
correlated	VVN	correlate
with	IN	with
ESR	NP	<unknown>
,	,	,
hs-CRP	NP	<unknown>
,	,	,
lipid	NN	lipid
profile	NN	profile
,	,	,
cIMT	NN	<unknown>
,	,	,
and	CC	and
FMD	JJ	<unknown>
%	NN	%
in	IN	in
RA	NP	RA
patients	NNS	patient
;	:	;
therefore	RB	therefore
,	,	,
it	PP	it
can	MD	can
be	VB	be
used	VVN	use
as	IN	as
an	DT	an
index	NN	index
to	TO	to
measure	VV	measure
disease	NN	disease
activity	NN	activity
as	RB	as
well	RB	well
as	IN	as
subclinical	JJ	subclinical
cardiovascular	JJ	cardiovascular
affection	NN	affection
in	IN	in
RA	NP	RA
patients	NNS	patient
.	SENT	.
T.	NP	T.
Harnessing	NP	<unknown>
Apoptotic	NP	<unknown>
Cell	NP	<unknown>
Clearance	NP	<unknown>
to	TO	to
Treat	NP	Treat
Autoimmune	NP	<unknown>
Arthritis	NP	<unknown>
.	SENT	.
A.	NP	A.
Early-stage	NP	<unknown>
apoptotic	JJ	<unknown>
cells	NNS	cell
possess	VVP	possess
immunomodulatory	JJ	<unknown>
properties	NNS	property
.	SENT	.
Proper	JJ	proper
apoptotic	JJ	<unknown>
cell	NN	cell
clearance	NN	clearance
during	IN	during
homeostasis	NN	homeostasis
has	VHZ	have
been	VBN	be
shown	VVN	show
to	TO	to
limit	VV	limit
subsequent	JJ	subsequent
immune	JJ	immune
responses	NNS	response
.	SENT	.
Based	VVN	base
on	IN	on
these	DT	these
observations	NNS	observation
,	,	,
early-stage	NN	early-stage
apoptotic	JJ	<unknown>
cell	NN	cell
infusion	NN	infusion
has	VHZ	have
been	VBN	be
used	VVN	use
to	TO	to
prevent	VV	prevent
unwanted	JJ	unwanted
inflammatory	JJ	inflammatory
responses	NNS	response
in	IN	in
different	JJ	different
experimental	JJ	experimental
models	NNS	model
of	IN	of
autoimmune	JJ	autoimmune
diseases	NNS	disease
or	CC	or
transplantation	NN	transplantation
.	SENT	.
Moreover	RB	moreover
,	,	,
this	DT	this
approach	NN	approach
has	VHZ	have
been	VBN	be
shown	VVN	show
to	TO	to
be	VB	be
feasible	JJ	feasible
without	IN	without
any	DT	any
toxicity	NN	toxicity
in	IN	in
patients	NNS	patient
undergoing	VVG	undergo
allogeneic	JJ	<unknown>
hematopoietic	JJ	hematopoietic
cell	NN	cell
transplantation	NN	transplantation
to	TO	to
prevent	VV	prevent
graft-versus-host	NN	<unknown>
disease	NN	disease
.	SENT	.
However	RB	however
,	,	,
whether	IN	whether
early-stage	NN	early-stage
apoptotic	JJ	<unknown>
cell	NN	cell
infusion	NN	infusion
can	MD	can
be	VB	be
used	VVN	use
to	TO	to
treat	VV	treat
ongoing	JJ	ongoing
inflammatory	JJ	inflammatory
disorders	NNS	disorder
has	VHZ	have
not	RB	not
been	VBN	be
reported	VVN	report
extensively	RB	extensively
.	SENT	.
Recently	RB	recently
,	,	,
we	PP	we
have	VHP	have
provided	VVN	provide
evidence	NN	evidence
that	IN/that	that
early-stage	NN	early-stage
apoptotic	JJ	<unknown>
cell	NN	cell
infusion	NN	infusion
is	VBZ	be
able	JJ	able
to	TO	to
control	VV	control
,	,	,
at	IN	at
least	JJS	least
transiently	RB	transiently
,	,	,
ongoing	JJ	ongoing
collagen-induced	JJ	<unknown>
arthritis	NN	arthritis
.	SENT	.
This	DT	this
beneficial	JJ	beneficial
therapeutic	JJ	therapeutic
effect	NN	effect
is	VBZ	be
associated	VVN	associate
with	IN	with
the	DT	the
modulation	NN	modulation
of	IN	of
antigen-presenting	JJ	<unknown>
cell	NN	cell
functions	NNS	function
mainly	RB	mainly
of	IN	of
macrophages	NNS	macrophage
and	CC	and
plasmacytoid	JJ	<unknown>
dendritic	JJ	dendritic
cells	NNS	cell
,	,	,
as	RB	as
well	RB	well
as	IN	as
the	DT	the
induction	NN	induction
of	IN	of
collagen-specific	JJ	<unknown>
regulatory	JJ	regulatory
CD4(+	NN	<unknown>
)	)	)
T	NN	T
cells	NNS	cell
(	(	(
Treg	NP	Treg
)	)	)
.	SENT	.
Furthermore	RB	furthermore
,	,	,
the	DT	the
efficacy	NN	efficacy
of	IN	of
this	DT	this
approach	NN	approach
is	VBZ	be
not	RB	not
altered	VVN	alter
by	IN	by
the	DT	the
association	NN	association
with	IN	with
two	CD	two
standard	JJ	standard
treatments	NNS	treatment
of	IN	of
rheumatoid	JJ	rheumatoid
arthritis	NN	arthritis
(	(	(
RA	NP	RA
)	)	)
,	,	,
methotrexate	NN	methotrexate
and	CC	and
tumor	NN	tumor
necrosis	NN	necrosis
factor	NN	factor
(	(	(
TNF	NP	TNF
)	)	)
inhibition	NN	inhibition
.	SENT	.
Here	RB	here
,	,	,
in	IN	in
the	DT	the
light	NN	light
of	IN	of
these	DT	these
observations	NNS	observation
and	CC	and
recent	JJ	recent
data	NNS	datum
of	IN	of
the	DT	the
literature	NN	literature
,	,	,
we	PP	we
discuss	VVP	discuss
the	DT	the
mechanisms	NNS	mechanism
of	IN	of
early-stage	NN	early-stage
apoptotic	JJ	<unknown>
cell	NN	cell
infusion	NN	infusion
and	CC	and
how	WRB	how
this	DT	this
therapeutic	JJ	therapeutic
approach	NN	approach
can	MD	can
be	VB	be
transposed	VVN	transpose
to	TO	to
patients	NNS	patient
with	IN	with
RA	NP	RA
.	SENT	.
T.	NP	T.
Morbid	NP	<unknown>
Sequences	NP	<unknown>
Suggest	NP	<unknown>
Molecular	NP	<unknown>
Mimicry	NP	<unknown>
between	IN	between
Microbial	NP	<unknown>
Peptides	NP	<unknown>
and	CC	and
Self-Antigens	NP	<unknown>
:	:	:
A	DT	a
Possibility	NN	possibility
of	IN	of
Inciting	VVG	incite
Autoimmunity	NN	<unknown>
.	SENT	.
A.	NP	A.
Understanding	NP	<unknown>
etiology	NN	etiology
of	IN	of
autoimmune	JJ	autoimmune
diseases	NNS	disease
has	VHZ	have
been	VBN	be
a	DT	a
great	JJ	great
challenge	NN	challenge
for	IN	for
designing	VVG	design
drugs	NNS	drug
and	CC	and
vaccines	NNS	vaccine
.	SENT	.
The	DT	the
pathophysiology	NN	<unknown>
of	IN	of
many	JJ	many
autoimmune	JJ	autoimmune
diseases	NNS	disease
may	MD	may
be	VB	be
attributed	VVN	attribute
to	TO	to
molecular	JJ	molecular
mimicry	NN	mimicry
provoked	VVN	provoke
by	IN	by
microbes	NNS	microbe
.	SENT	.
Molecular	JJ	molecular
mimicry	NN	mimicry
hypothesizes	VVZ	hypothesize
that	IN/that	that
a	DT	a
sequence	NN	sequence
homology	NN	homology
between	IN	between
foreign	JJ	foreign
and	CC	and
self-peptides	NNS	<unknown>
leads	VVZ	lead
to	TO	to
cross-activation	NN	<unknown>
of	IN	of
autoreactive	NN	<unknown>
T	NN	T
cells	NNS	cell
.	SENT	.
Different	JJ	different
microbial	JJ	microbial
proteins	NNS	protein
are	VBP	be
implicated	VVN	implicate
in	IN	in
various	JJ	various
autoimmune	JJ	autoimmune
diseases	NNS	disease
,	,	,
including	VVG	include
multiple	JJ	multiple
sclerosis	NN	sclerosis
,	,	,
human	JJ	human
type	NN	type
1	CD	@card@
diabetes	NN	diabetes
,	,	,
primary	JJ	primary
biliary	JJ	biliary
cirrhosis	NN	cirrhosis
and	CC	and
rheumatoid	JJ	rheumatoid
arthritis	NN	arthritis
.	SENT	.
It	PP	it
may	MD	may
be	VB	be
imperative	JJ	imperative
to	TO	to
identify	VV	identify
the	DT	the
microbial	JJ	microbial
epitopes	NNS	<unknown>
that	WDT	that
initiate	VVP	initiate
the	DT	the
activation	NN	activation
of	IN	of
autoreactive	NN	<unknown>
T	NN	T
cells	NNS	cell
.	SENT	.
Consequently	RB	consequently
,	,	,
in	IN	in
the	DT	the
present	JJ	present
study	NN	study
,	,	,
we	PP	we
employed	VVD	employ
immunoinformatics	NN	<unknown>
tools	NNS	tool
to	TO	to
delineate	VV	delineate
homologous	JJ	homologous
antigenic	JJ	antigenic
regions	NNS	region
between	IN	between
microbes	NNS	microbe
and	CC	and
human	JJ	human
proteins	NNS	protein
at	IN	at
not	RB	not
only	RB	only
the	DT	the
sequence	NN	sequence
level	NN	level
but	CC	but
at	IN	at
the	DT	the
structural	JJ	structural
level	NN	level
too	RB	too
.	SENT	.
Interestingly	RB	interestingly
,	,	,
many	JJ	many
cross-reactive	JJ	<unknown>
MHC	NP	MHC
class	NN	class
II	NP	II
binding	JJ	binding
epitopes	NNS	<unknown>
were	VBD	be
detected	VVN	detect
from	IN	from
an	DT	an
array	NN	array
of	IN	of
microbes	NNS	microbe
.	SENT	.
Further	RBR	further
,	,	,
these	DT	these
peptides	NNS	peptide
possess	VVP	possess
a	DT	a
potential	NN	potential
to	TO	to
skew	VV	skew
immune	JJ	immune
response	NN	response
toward	IN	toward
Th1-like	JJ	<unknown>
patterns	NNS	pattern
.	SENT	.
The	DT	the
present	JJ	present
study	NN	study
divulges	VVZ	divulge
many	JJ	many
microbial	JJ	microbial
target	NN	target
proteins	NNS	protein
,	,	,
their	PP$	their
putative	JJ	putative
MHC-binding	NN	<unknown>
epitopes	NNS	<unknown>
,	,	,
and	CC	and
predicted	VVD	predict
structures	NNS	structure
to	TO	to
establish	VV	establish
the	DT	the
fact	NN	fact
that	IN/that	that
both	DT	both
sequence	NN	sequence
and	CC	and
structure	NN	structure
are	VBP	be
two	CD	two
important	JJ	important
aspects	NNS	aspect
for	IN	for
understanding	VVG	understand
the	DT	the
relationship	NN	relationship
between	IN	between
molecular	JJ	molecular
mimicry	NN	mimicry
and	CC	and
autoimmune	JJ	autoimmune
diseases	NNS	disease
.	SENT	.
Such	JJ	such
findings	NNS	finding
may	MD	may
enable	VV	enable
us	PP	us
in	IN	in
designing	VVG	design
potential	JJ	potential
immunotherapies	NNS	immunotherapy
to	TO	to
tolerize	VV	<unknown>
autoreactive	NN	<unknown>
T	NN	T
cells	NNS	cell
.	SENT	.
T.	NP	T.
Outcomes	NP	<unknown>
of	IN	of
lupus	NN	lupus
and	CC	and
rheumatoid	JJ	rheumatoid
arthritis	NN	arthritis
patients	NNS	patient
with	IN	with
primary	JJ	primary
dengue	NN	dengue
infection	NN	infection
:	:	:
A	DT	a
seven-year	JJ	seven-year
report	NN	report
from	IN	from
Brazil	NP	Brazil
.	SENT	.
A.	NP	A.
We	PP	we
described	VVD	describe
the	DT	the
clinical	JJ	clinical
profile	NN	profile
and	CC	and
outcomes	NNS	outcome
of	IN	of
patients	NNS	patient
with	IN	with
SLE	NP	<unknown>
and	CC	and
RA	NP	RA
diseases	NNS	disease
reported	VVD	report
to	TO	to
the	DT	the
Brazilian	JJ	Brazilian
Health	NP	Health
Information	NP	Information
System	NP	System
with	IN	with
primary	JJ	primary
dengue	NN	dengue
infection.Databases	NNS	<unknown>
from	IN	from
the	DT	the
Brazilian	JJ	Brazilian
Public	NP	Public
Health	NP	Health
Informatics	NN	Informatics
System	NP	System
(	(	(
SUS	NP	<unknown>
)	)	)
were	VBD	be
linked	VVN	link
as	IN	as
the	DT	the
source	NN	source
of	IN	of
information	NN	information
.	SENT	.
Three	CD	three
databases	NNS	database
comprising	VVG	comprise
different	JJ	different
longitudinal	JJ	longitudinal
information	NN	information
of	IN	of
lupus	NN	lupus
or	CC	or
rheumatoid	JJ	rheumatoid
arthritis	NN	arthritis
(	(	(
RA	NP	RA
)	)	)
patients	NNS	patient
under	IN	under
treatment	NN	treatment
and	CC	and
care	NN	care
through	IN	through
the	DT	the
Brazilian	JJ	Brazilian
Health	NP	Health
System	NP	System
were	VBD	be
linked	VVN	link
.	SENT	.
Patients	NNS	patient
who	WP	who
had	VHD	have
lupus	NN	lupus
ICD-9	NN	<unknown>
code	NN	code
or	CC	or
RA	NP	RA
ICD-9	NP	<unknown>
code	NN	code
and	CC	and
their	PP$	their
treatment	NN	treatment
approved	VVN	approve
by	IN	by
SUS	NP	<unknown>
were	VBD	be
included	VVN	include
in	IN	in
the	DT	the
study	NN	study
.	SENT	.
In	IN	in
Study	NP	Study
1	CD	@card@
,	,	,
we	PP	we
described	VVD	describe
the	DT	the
clinical	JJ	clinical
characteristics	NNS	characteristic
of	IN	of
RA/lupus	NP	<unknown>
patients	NNS	patient
who	WP	who
had	VHD	have
dengue	NN	dengue
infection	NN	infection
.	SENT	.
In	IN	in
Study	NP	Study
2	CD	@card@
,	,	,
we	PP	we
compared	VVD	compare
RA/lupus	NP	<unknown>
patients	NNS	patient
with	IN	with
or	CC	or
without	IN	without
dengue	NN	dengue
for	IN	for
hospitalization	NN	hospitalization
rates	NNS	rate
after	IN	after
index	NN	index
dengue	NN	dengue
diagnosis	NN	diagnosis
for	IN	for
dengue-exposed	JJ	<unknown>
or	CC	or
matching	VVG	match
date	NN	date
for	IN	for
dengue-unexposed.We	NP	<unknown>
included	VVD	include
69	CD	@card@
SLE	NP	<unknown>
and	CC	and
301	CD	@card@
RA	NP	RA
patients	NNS	patient
with	IN	with
dengue	NN	dengue
.	SENT	.
In	IN	in
the	DT	the
RA/lupus	NP	<unknown>
with	IN	with
dengue	NN	dengue
case	NN	case
series	NN	series
,	,	,
hospitalization	NN	hospitalization
was	VBD	be
found	VVN	find
in	IN	in
24.6	CD	@card@
%	NN	%
of	IN	of
lupus	NN	lupus
subjects	NNS	subject
and	CC	and
of	IN	of
11.2	CD	@card@
%	NN	%
of	IN	of
RA	NP	RA
subjects	NNS	subject
.	SENT	.
It	PP	it
differed	VVD	differ
by	IN	by
geographic	JJ	geographic
region	NN	region
(	(	(
p	NN	p
=	SYM	=
0.03	CD	@card@
)	)	)
,	,	,
gender	NN	gender
(	(	(
p	NN	p
=	SYM	=
0.05	CD	@card@
)	)	)
and	CC	and
the	DT	the
use	NN	use
of	IN	of
azathioprine	NN	azathioprine
(	(	(
p	NN	p
=	SYM	=
0.02	CD	@card@
)	)	)
.	SENT	.
Dengue	NN	dengue
was	VBD	be
the	DT	the
most	RBS	most
frequent	JJ	frequent
reason	NN	reason
for	IN	for
hospitalization	NN	hospitalization
reported	VVN	report
(	(	(
43.0	CD	@card@
%	NN	%
)	)	)
.	SENT	.
Hospitalization	NN	hospitalization
due	JJ	due
to	TO	to
dengue	NN	dengue
was	VBD	be
noted	VVN	note
in	IN	in
12	CD	@card@
(	(	(
42.9	CD	@card@
%	NN	%
)	)	)
dengue-exposed	JJ	<unknown>
patients	NNS	patient
(	(	(
p	NN	p
=	SYM	=
0.02	CD	@card@
)	)	)
,	,	,
while	IN	while
rheumatoid	JJ	rheumatoid
arthritis	NN	arthritis
was	VBD	be
reported	VVN	report
as	IN	as
the	DT	the
cause	NN	cause
of	IN	of
hospitalization	NN	hospitalization
in	IN	in
22.2	CD	@card@
%	NN	%
of	IN	of
dengue-unexposed	JJ	<unknown>
(	(	(
p	NN	p
=	SYM	=
0.005	CD	@card@
)	)	)
.	SENT	.
Five	CD	five
deaths	NNS	death
were	VBD	be
reported	VVN	report
among	IN	among
the	DT	the
dengue-exposed	JJ	<unknown>
and	CC	and
none	NN	none
among	IN	among
dengue-unexposed	JJ	<unknown>
.	SENT	.
Bacterial	JJ	bacterial
infection	NN	infection
was	VBD	be
the	DT	the
most	RBS	most
frequent	JJ	frequent
cause	NN	cause
of	IN	of
death	NN	death
.	SENT	.
We	PP	we
found	VVD	find
that	IN/that	that
the	DT	the
dengue	NN	dengue
exposure	NN	exposure
was	VBD	be
associated	VVN	associate
with	IN	with
an	DT	an
increased	VVN	increase
risk	NN	risk
of	IN	of
hospitalization	NN	hospitalization
outcome	NN	outcome
in	IN	in
RA	NP	RA
and	CC	and
lupus	NN	lupus
patients	NNS	patient
(	(	(
RR	NP	RR
=	SYM	=
6.2	CD	@card@
;	:	;
95	CD	@card@
%	NN	%
CI	NP	<unknown>
:	:	:
2.99-12.94).We	NP	<unknown>
found	VVD	find
that	IN/that	that
when	WRB	when
comparing	VVG	compare
RA/lupus	NP	<unknown>
patients	NNS	patient
with	IN	with
or	CC	or
without	IN	without
dengue	NN	dengue
,	,	,
dengue-exposed	JJ	<unknown>
patients	NNS	patient
had	VHD	have
an	DT	an
increased	VVN	increase
rates	NNS	rate
of	IN	of
hospitalization	NN	hospitalization
and	CC	and
death	NN	death
.	SENT	.
T.	NP	T.
Neurologic	NP	<unknown>
Manifestations	NP	<unknown>
of	IN	of
Rheumatoid	NP	<unknown>
Arthritis	NP	<unknown>
.	SENT	.
A.	NP	A.
Neurologic	NP	<unknown>
manifestations	NNS	manifestation
of	IN	of
rheumatoid	JJ	rheumatoid
arthritis	NN	arthritis
(	(	(
RA	NP	RA
)	)	)
range	NN	range
in	IN	in
severity	NN	severity
from	IN	from
mild	JJ	mild
paresthesias	NNS	paresthesia
in	IN	in
the	DT	the
hand	NN	hand
from	IN	from
carpal	NN	carpal
tunnel	NN	tunnel
syndrome	NN	syndrome
to	TO	to
sudden	JJ	sudden
death	NN	death
due	JJ	due
to	TO	to
impingement	NN	impingement
of	IN	of
the	DT	the
medulla	NN	medulla
by	IN	by
an	DT	an
eroded	VVN	erode
,	,	,
vertically	RB	vertically
subluxed	JJ	<unknown>
dens	NNS	den
.	SENT	.
Most	RBS	most
neurologic	JJ	neurologic
complications	NNS	complication
are	VBP	be
a	DT	a
consequence	NN	consequence
of	IN	of
articular	JJ	articular
inflammation	NN	inflammation
and	CC	and
damage	NN	damage
that	WDT	that
leads	VVZ	lead
to	TO	to
compression	NN	compression
of	IN	of
adjacent	JJ	adjacent
structures	NNS	structure
of	IN	of
the	DT	the
central	JJ	central
or	CC	or
peripheral	JJ	peripheral
nervous	JJ	nervous
systems	NNS	system
.	SENT	.
Rare	JJ	rare
but	CC	but
serious	JJ	serious
extra-articular	JJ	<unknown>
manifestations	NNS	manifestation
include	VVP	include
inflammation	NN	inflammation
of	IN	of
the	DT	the
meninges	NNS	meninx
and	CC	and
ischemic	JJ	ischemic
neuropathies	NNS	neuropathy
due	JJ	due
to	TO	to
necrotizing	VVG	<unknown>
arteritis	NN	arteritis
of	IN	of
the	DT	the
vasa	NNS	vasa
vasorum	NN	<unknown>
.	SENT	.
Medical	JJ	medical
therapy	NN	therapy
with	IN	with
synthetic	JJ	synthetic
disease-modifying	JJ	<unknown>
antirheumatic	JJ	<unknown>
drugs	NNS	drug
and	CC	and
biological	JJ	biological
agents	NNS	agent
has	VHZ	have
diminished	VVN	diminish
the	DT	the
incidence	NN	incidence
of	IN	of
serious	JJ	serious
neurologic	JJ	neurologic
manifestations	NNS	manifestation
in	IN	in
RA	NP	RA
.	SENT	.
T.	NP	T.
[	SYM	[
analysis	NN	analysis
of	IN	of
adherence	NN	adherence
and	CC	and
compliance	NN	compliance
to	TO	to
methotrexate	NN	methotrexate
therapy	NN	therapy
in	IN	in
rheumatoid	JJ	rheumatoid
arthritis	NN	arthritis
patients	NNS	patient
]	SYM	]
.	SENT	.
A.	NP	A.
Rheumatoid	NP	<unknown>
arthritis	NN	arthritis
is	VBZ	be
chronic	JJ	chronic
inflammatory	JJ	inflammatory
disease	NN	disease
leading	VVG	lead
to	TO	to
disability	NN	disability
and	CC	and
increasing	VVG	increase
the	DT	the
risk	NN	risk
of	IN	of
premature	JJ	premature
death	NN	death
.	SENT	.
Early	JJ	early
treatment	NN	treatment
is	VBZ	be
crucial	JJ	crucial
for	IN	for
remission	NN	remission
and	CC	and
maintaining	VVG	maintain
it	PP	it
for	IN	for
a	DT	a
maximal	JJ	maximal
time	NN	time
.	SENT	.
Adherence	NN	adherence
of	IN	of
the	DT	the
patient	NN	patient
to	TO	to
the	DT	the
therapeutic	JJ	therapeutic
recommendations	NNS	recommendation
is	VBZ	be
necessary	JJ	necessary
.	SENT	.
Although	IN	although
this	DT	this
issue	NN	issue
is	VBZ	be
important	JJ	important
,	,	,
its	PP$	its
role	NN	role
in	IN	in
achieving	VVG	achieve
of	IN	of
therapeutic	JJ	therapeutic
success	NN	success
is	VBZ	be
not	RB	not
fully	RB	fully
noted	VVN	note
by	IN	by
patients	NNS	patient
as	RB	as
well	RB	well
as	IN	as
medical	JJ	medical
stuff	NN	stuff
.	SENT	.
Patients	NNS	patient
with	IN	with
RA	NP	RA
are	VBP	be
often	RB	often
non-adherent	JJ	<unknown>
to	TO	to
rheumatologist	NN	rheumatologist
's	POS	's
recommendations	NNS	recommendation
and	CC	and
non-compliance	NN	non-compliance
to	TO	to
the	DT	the
therapy	NN	therapy
regimen	NN	regimen
.	SENT	.
The	DT	the
causes	NNS	cause
of	IN	of
this	DT	this
phenomenon	NN	phenomenon
are	VBP	be
numerous	JJ	numerous
and	CC	and
lie	VV	lie
in	IN	in
the	DT	the
patient	NN	patient
's	POS	's
attitude	NN	attitude
to	TO	to
therapy	NN	therapy
or	CC	or
are	VBP	be
patient-independent	JJ	<unknown>
.	SENT	.
To	TO	to
effectively	RB	effectively
increase	VV	increase
the	DT	the
level	NN	level
of	IN	of
adherence	NN	adherence
and	CC	and
compliance	NN	compliance
,	,	,
the	DT	the
detailed	JJ	detailed
medical	JJ	medical
care	NN	care
,	,	,
including	VVG	include
education	NN	education
of	IN	of
the	DT	the
patient	NN	patient
,	,	,
as	RB	as
well	RB	well
as	IN	as
adaptation	NN	adaptation
of	IN	of
the	DT	the
drug	NN	drug
form	NN	form
,	,	,
by	IN	by
concentrating	VVG	concentrate
the	DT	the
active	JJ	active
compound	NN	compound
,	,	,
is	VBZ	be
essential	JJ	essential
.	SENT	.
T.	NP	T.
Multicentric	NP	<unknown>
Reticulohistiocytosis	NN	<unknown>
:	:	:
A	DT	a
Multicenter	NP	<unknown>
Case	NP	Case
Series	NP	Series
and	CC	and
Review	NP	Review
of	IN	of
Literature	NP	<unknown>
.	SENT	.
A.	NP	A.
Multicentric	NP	<unknown>
reticulohistiocytosis	NN	<unknown>
is	VBZ	be
a	DT	a
rare	JJ	rare
systemic	JJ	systemic
disease	NN	disease
characterized	VVN	characterize
by	IN	by
the	DT	the
presence	NN	presence
of	IN	of
non-Langerhans	NP	<unknown>
cell	NN	cell
histiocytic	JJ	histiocytic
infiltrate	NN	infiltrate
in	IN	in
several	JJ	several
organ	NN	organ
systems	NNS	system
.	SENT	.
Because	IN	because
its	PP$	its
clinical	JJ	clinical
presentation	NN	presentation
so	RB	so
closely	RB	closely
resembles	VVZ	resemble
autoimmune	JJ	autoimmune
conditions	NNS	condition
such	JJ	such
as	IN	as
rheumatoid	JJ	rheumatoid
arthritis	NN	arthritis
,	,	,
it	PP	it
is	VBZ	be
often	RB	often
overlooked	VVN	overlook
as	IN	as
a	DT	a
diagnosis	NN	diagnosis
and	CC	and
,	,	,
even	RB	even
when	WRB	when
recognized	VVN	recognize
,	,	,
presents	VVZ	present
a	DT	a
challenge	NN	challenge
for	IN	for
treatment	NN	treatment
because	IN	because
of	IN	of
a	DT	a
lack	NN	lack
of	IN	of
consensus	NN	consensus
regarding	VVG	regard
guidelines	NNS	guideline
for	IN	for
management	NN	management
.	SENT	.
We	PP	we
here	RB	here
review	VV	review
6	CD	@card@
cases	NNS	case
of	IN	of
multicentric	JJ	<unknown>
reticulohistiocytosis	NN	<unknown>
(	(	(
MRH	NP	<unknown>
)	)	)
from	IN	from
2	CD	@card@
institutions	NNS	institution
to	TO	to
identify	VV	identify
clinical	JJ	clinical
features	NNS	feature
,	,	,
treatment	NN	treatment
,	,	,
and	CC	and
outcomes	NNS	outcome
of	IN	of
MRH.We	NP	<unknown>
identified	VVD	identify
6	CD	@card@
patients	NNS	patient
with	IN	with
MRH	NP	<unknown>
and	CC	and
reviewed	VVD	review
their	PP$	their
medical	JJ	medical
records	NNS	record
to	TO	to
assess	VV	assess
demographic	JJ	demographic
data	NNS	datum
,	,	,
clinical	JJ	clinical
presentations	NNS	presentation
,	,	,
laboratory	NN	laboratory
findings	NNS	finding
,	,	,
comorbid	JJ	<unknown>
conditions	NNS	condition
,	,	,
histopathologic	JJ	<unknown>
features	NNS	feature
,	,	,
and	CC	and
pharmacotherapies.All	NN	<unknown>
6	CD	@card@
patients	NNS	patient
had	VHD	have
definite	JJ	definite
MRH	NN	<unknown>
as	IN	as
established	VVN	establish
by	IN	by
skin	NN	skin
biopsy	NN	biopsy
.	SENT	.
All	PDT	all
our	PP$	our
patients	NNS	patient
were	VBD	be
middle-aged	JJ	middle-aged
white	JJ	white
women	NNS	woman
in	IN	in
whom	WP	whom
skin	NN	skin
involvement	NN	involvement
preceded	VVN	precede
arthritic	JJ	arthritic
symptoms	NNS	symptom
.	SENT	.
Hand	NN	hand
and	CC	and
knee	NN	knee
involvement	NN	involvement
was	VBD	be
most	RBS	most
common	JJ	common
,	,	,
seen	VVN	see
in	IN	in
5	CD	@card@
and	CC	and
4	CD	@card@
patients	NNS	patient
,	,	,
respectively	RB	respectively
.	SENT	.
Erosions	NNS	erosion
of	IN	of
the	DT	the
distal	JJ	distal
interphalangeal	NN	<unknown>
joints	NNS	joint
were	VBD	be
the	DT	the
most	RBS	most
common	JJ	common
radiographic	JJ	radiographic
abnormality	NN	abnormality
,	,	,
seen	VVN	see
in	IN	in
3	CD	@card@
patients	NNS	patient
.	SENT	.
Diagnosis	NN	diagnosis
of	IN	of
MRH	NP	<unknown>
was	VBD	be
usually	RB	usually
delayed	VVN	delay
,	,	,
and	CC	and
once	RB	once
identified	VVN	identify
,	,	,
treatment	NN	treatment
and	CC	and
the	DT	the
outcomes	NNS	outcome
of	IN	of
these	DT	these
treatments	NNS	treatment
varied	VVD	vary
considerably	RB	considerably
.	SENT	.
Approximately	RB	approximately
50	CD	@card@
%	NN	%
of	IN	of
our	PP$	our
patients	NNS	patient
had	VHD	have
concomitant	JJ	concomitant
hypothyroidism	NN	hypothyroidism
and	CC	and
hyperlipidemia	NN	<unknown>
.	SENT	.
None	NN	none
were	VBD	be
subsequently	RB	subsequently
diagnosed	VVN	diagnose
with	IN	with
malignancy.Multicentric	JJ	<unknown>
reticulohistiocytosis	NN	<unknown>
is	VBZ	be
a	DT	a
rare	JJ	rare
but	CC	but
often	RB	often
overlooked	VVD	overlook
systemic	JJ	systemic
disease	NN	disease
that	IN/that	that
rheumatologists	NNS	<unknown>
are	VBP	be
liable	JJ	liable
to	TO	to
encounter	VV	encounter
in	IN	in
their	PP$	their
clinical	JJ	clinical
practice	NN	practice
.	SENT	.
The	DT	the
presence	NN	presence
of	IN	of
cutaneous	JJ	cutaneous
findings	NNS	finding
,	,	,
erosive	JJ	erosive
disease	NN	disease
involving	VVG	involve
the	DT	the
distal	JJ	distal
interphalangeal	JJ	<unknown>
joints	NNS	joint
,	,	,
and	CC	and
comorbid	JJ	<unknown>
diseases	NNS	disease
,	,	,
such	JJ	such
as	IN	as
hyperlipidemia	NN	<unknown>
and	CC	and
hypothyroidism	NN	hypothyroidism
,	,	,
are	VBP	be
features	NNS	feature
that	WDT	that
should	MD	should
prompt	VV	prompt
practitioners	NNS	practitioner
to	TO	to
consider	VV	consider
pursuing	VVG	pursue
a	DT	a
biopsy	NN	biopsy
of	IN	of
the	DT	the
affected	JJ	affected
tissue	NN	tissue
in	IN	in
order	NN	order
to	TO	to
confirm	VV	confirm
or	CC	or
refute	VV	refute
the	DT	the
diagnosis	NN	diagnosis
of	IN	of
MRH	NP	<unknown>
.	SENT	.
Bisphosphonates	NP	<unknown>
alone	RB	alone
may	MD	may
not	RB	not
be	VB	be
able	JJ	able
to	TO	to
control	VV	control
disease	NN	disease
activity	NN	activity
,	,	,
and	CC	and
patients	NNS	patient
are	VBP	be
likely	JJ	likely
to	TO	to
need	VV	need
immunosuppressive	JJ	<unknown>
agents	NNS	agent
for	IN	for
better	JJR	good
control	NN	control
.	SENT	.
T.	NP	T.
The	DT	the
Role	NN	role
of	IN	of
Innate	JJ	innate
lymphoid	JJ	lymphoid
cells	NNS	cell
in	IN	in
health	NN	health
and	CC	and
disease	NN	disease
.	SENT	.
A.	NP	A.
Innate	JJ	innate
lymphoid	JJ	lymphoid
cells	NNS	cell
(	(	(
ILCs	NP	<unknown>
)	)	)
are	VBP	be
kind	NN	kind
of	IN	of
innate	JJ	innate
immune	JJ	immune
cells	NNS	cell
which	WDT	which
can	MD	can
be	VB	be
divided	VVN	divide
into	IN	into
three	CD	three
main	JJ	main
subsets	NNS	subset
according	VVG	accord
to	TO	to
their	PP$	their
cytokine	NN	<unknown>
release	NN	release
profile	NN	profile
,	,	,
transcription	NN	transcription
factors	NNS	factor
,	,	,
and	CC	and
surface	NN	surface
markers	NNS	marker
.	SENT	.
ILCs	NNS	<unknown>
affect	VVP	affect
the	DT	the
initial	JJ	initial
stages	NNS	stage
of	IN	of
immunity	NN	immunity
in	IN	in
response	NN	response
to	TO	to
microbes	NNS	microbe
and	CC	and
participate	VV	participate
in	IN	in
immunity	NN	immunity
,	,	,
inflammation	NN	inflammation
and	CC	and
tissue	NN	tissue
repair	NN	repair
.	SENT	.
ILCs	NNS	<unknown>
modulate	VVP	modulate
immunity	NN	immunity
through	IN	through
resistance	NN	resistance
to	TO	to
the	DT	the
pathogens	NNS	pathogen
and	CC	and
regulation	NN	regulation
of	IN	of
autoimmune	JJ	autoimmune
inflammation	NN	inflammation
and	CC	and
metabolic	JJ	metabolic
homeostasis	NN	homeostasis
.	SENT	.
Therefore	RB	therefore
dysregulation	NN	<unknown>
of	IN	of
ILCs	NP	<unknown>
may	MD	may
lead	VV	lead
to	TO	to
chronic	JJ	chronic
pathologies	NNS	pathology
such	JJ	such
as	IN	as
allergies	NNS	allergy
(	(	(
i.e.	FW	i.e.
asthma	NN	asthma
)	)	)
,	,	,
inflammation	NN	inflammation
(	(	(
i.e.	FW	i.e.
inflammatory	JJ	inflammatory
bowel	NN	bowel
disease	NN	disease
)	)	)
and	CC	and
autoimmunity	NN	<unknown>
(	(	(
i.e.	FW	i.e.
psoriasis	NN	psoriasis
,	,	,
atopic	JJ	<unknown>
dermatitis	NN	dermatitis
,	,	,
rheumatoid	JJ	rheumatoid
arthritis	NN	arthritis
,	,	,
multiple	JJ	multiple
sclerosis	NN	sclerosis
,	,	,
and	CC	and
ankylosing	VVG	ankylose
spondylitis	NN	spondylitis
)	)	)
.	SENT	.
Regarding	VVG	regard
the	DT	the
critical	JJ	critical
role	NN	role
of	IN	of
ILCs	NP	<unknown>
in	IN	in
the	DT	the
regulation	NN	regulation
of	IN	of
immune	JJ	immune
system	NN	system
,	,	,
the	DT	the
elucidation	NN	elucidation
of	IN	of
their	PP$	their
function	NN	function
in	IN	in
different	JJ	different
conditions	NNS	condition
makes	VVZ	make
an	DT	an
interesting	JJ	interesting
target	NN	target
for	IN	for
improvement	NN	improvement
of	IN	of
novel	JJ	novel
therapeutic	JJ	therapeutic
approach	NN	approach
to	TO	to
modulate	VV	modulate
an	DT	an
immune	JJ	immune
response	NN	response
in	IN	in
different	JJ	different
disease	NN	disease
context	NN	context
.	SENT	.
This	DT	this
article	NN	article
is	VBZ	be
protected	VVN	protect
by	IN	by
copyright	NN	copyright
.	SENT	.
All	DT	all
rights	NNS	right
reserved	VVD	reserve
.	SENT	.
T.	NP	T.
Switching	NP	Switching
Between	IN	between
Biological	NP	Biological
Treatments	NP	<unknown>
in	IN	in
Psoriatic	NP	<unknown>
Arthritis	NP	<unknown>
:	:	:
A	DT	a
Review	NP	Review
of	IN	of
the	DT	the
Evidence	NN	evidence
.	SENT	.
A.	NP	A.
Psoriatic	NP	<unknown>
arthritis	NN	arthritis
(	(	(
PsA	NP	<unknown>
)	)	)
is	VBZ	be
a	DT	a
chronic	JJ	chronic
inflammatory	JJ	inflammatory
arthropathy	NN	<unknown>
.	SENT	.
Therapy	NN	therapy
with	IN	with
anti-tumor	NP	anti-tumor
necrosis	NN	necrosis
factor	NN	factor
(	(	(
TNF)-α	NP	<unknown>
agents	NNS	agent
represents	VVZ	represent
the	DT	the
first	JJ	first
therapeutic	JJ	therapeutic
choice	NN	choice
for	IN	for
moderate	JJ	moderate
and	CC	and
severe	JJ	severe
forms	NNS	form
;	:	;
however	RB	however
,	,	,
PsA	NP	<unknown>
patients	NNS	patient
can	MD	can
experience	VV	experience
anti-TNFα	JJ	<unknown>
failure	NN	failure
,	,	,
lack	NN	lack
of	IN	of
efficacy	NN	efficacy
,	,	,
or	CC	or
adverse	JJ	adverse
events	NNS	event
.	SENT	.
Several	JJ	several
evidences	NNS	evidence
exist	VVP	exist
on	IN	on
the	DT	the
effectiveness	NN	effectiveness
of	IN	of
switching	VVG	switch
among	IN	among
different	JJ	different
TNFα	NP	<unknown>
inhibitors	NNS	inhibitor
,	,	,
and	CC	and
we	PP	we
reviewed	VVD	review
the	DT	the
published	VVN	publish
data	NNS	datum
on	IN	on
the	DT	the
effectiveness	NN	effectiveness
of	IN	of
anti-TNFα	JJ	<unknown>
first-	NN	<unknown>
,	,	,
second-	NN	second-
and	CC	and
third-line	NN	third-line
.	SENT	.
Most	JJS	most
of	IN	of
the	DT	the
studies	NNS	study
report	VVP	report
that	IN/that	that
the	DT	the
main	JJ	main
reason	NN	reason
for	IN	for
switching	VVG	switch
to	TO	to
a	DT	a
second	JJ	second
anti-TNFα	NN	<unknown>
agent	NN	agent
is	VBZ	be
represented	VVN	represent
by	IN	by
lack	NN	lack
of	IN	of
efficacy	NN	efficacy
(	(	(
primary	JJ	primary
or	CC	or
secondary	JJ	secondary
)	)	)
and	CC	and
,	,	,
more	RBR	more
rarely	RB	rarely
,	,	,
adverse	JJ	adverse
events	NNS	event
.	SENT	.
Switchers	NNS	switcher
receiving	VVG	receive
their	PP$	their
second	JJ	second
anti-TNFα	NN	<unknown>
agent	NN	agent
have	VHP	have
considerably	RB	considerably
poorer	JJR	poor
responses	NNS	response
compared	VVN	compare
with	IN	with
non-switchers	NNS	<unknown>
.	SENT	.
Survival	NN	survival
of	IN	of
anti-TNFα	JJ	<unknown>
treatment	NN	treatment
appears	VVZ	appear
to	TO	to
be	VB	be
superior	JJ	superior
in	IN	in
PsA	NP	<unknown>
patients	NNS	patient
when	WRB	when
compared	VVN	compare
with	IN	with
rheumatoid	JJ	rheumatoid
arthritis	NN	arthritis
patients	NNS	patient
.	SENT	.
Switching	VVG	switch
from	IN	from
anti-TNF	NN	<unknown>
agents	NNS	agent
to	TO	to
ustekinumab	NN	<unknown>
or	CC	or
secukinumab	NN	<unknown>
or	CC	or
apremilast	NN	<unknown>
can	MD	can
represent	VV	represent
a	DT	a
valid	JJ	valid
alternative	JJ	alternative
therapeutic	JJ	therapeutic
strategy	NN	strategy
.	SENT	.
T.	NP	T.
Circulating	NP	<unknown>
levels	NNS	level
of	IN	of
proinflammatory	JJ	<unknown>
mediators	NNS	mediator
as	IN	as
potential	JJ	potential
biomarkers	NNS	<unknown>
of	IN	of
post-traumatic	JJ	post-traumatic
knee	NN	knee
osteoarthritis	NN	osteoarthritis
development	NN	development
.	SENT	.
A.	NP	A.
The	DT	the
identification	NN	identification
of	IN	of
biomarkers	NNS	<unknown>
of	IN	of
post-traumatic	JJ	post-traumatic
osteoarthritis	NN	osteoarthritis
(	(	(
PTOA	NP	<unknown>
)	)	)
progression	NN	progression
is	VBZ	be
of	IN	of
clinical	JJ	clinical
importance	NN	importance
.	SENT	.
The	DT	the
aims	VVZ	aim
of	IN	of
this	DT	this
study	NN	study
were	VBD	be
:	:	:
(	(	(
1	LS	1
)	)	)
to	TO	to
assess	VV	assess
the	DT	the
abilities	NNS	ability
of	IN	of
various	JJ	various
soluble	JJ	soluble
proinflammatory	JJ	<unknown>
mediators	NNS	mediator
in	IN	in
plasma	NN	plasma
to	TO	to
distinguish	VV	distinguish
patients	NNS	patient
with	IN	with
knee	NN	knee
PTOA	NN	<unknown>
from	IN	from
controls	NNS	control
;	:	;
(	(	(
2	LS	2
)	)	)
to	TO	to
determine	VV	determine
the	DT	the
correlations	NNS	correlation
between	IN	between
the	DT	the
mediators	NNS	mediator
in	IN	in
plasma	NN	plasma
and	CC	and
those	DT	those
mediators	NNS	mediator
in	IN	in
synovial	JJ	synovial
fluid	NN	fluid
(	(	(
SF	NP	SF
)	)	)
;	:	;
and	CC	and
(	(	(
3	LS	3
)	)	)
to	TO	to
explore	VV	explore
the	DT	the
associations	NNS	association
of	IN	of
the	DT	the
mediators	NNS	mediator
with	IN	with
radiographic	JJ	radiographic
PTOA	NP	<unknown>
severity.The	NN	<unknown>
concentrations	NNS	concentration
of	IN	of
IL-1β	NP	<unknown>
,	,	,
IL-6	NP	<unknown>
,	,	,
IL-18	NP	<unknown>
,	,	,
TNFα	NP	<unknown>
,	,	,
and	CC	and
leptin	NN	<unknown>
were	VBD	be
measured	VVN	measure
using	VVG	use
ELISA	NP	Elisa
.	SENT	.
Nitric	JJ	nitric
oxide	NN	oxide
was	VBD	be
determined	VVN	determine
as	IN	as
nitrite/nitrate	NNS	<unknown>
(	(	(
NO	NP	No
x	NN	x
)	)	)
using	VVG	use
the	DT	the
Griess	NP	Griess
reaction.We	NP	<unknown>
included	VVD	include
171	CD	@card@
subjects	NNS	subject
(	(	(
134	CD	@card@
PTOA	NP	<unknown>
patients	NNS	patient
and	CC	and
37	CD	@card@
controls	NNS	control
)	)	)
and	CC	and
excluded	VVN	exclude
patients	NNS	patient
with	IN	with
rheumatoid	JJ	rheumatoid
arthritis	NN	arthritis
or	CC	or
gout	NN	gout
.	SENT	.
The	DT	the
ROC	NP	<unknown>
curve	NN	curve
of	IN	of
plasma	NN	plasma
NO	NP	No
x	NN	x
had	VHD	have
the	DT	the
highest	JJS	high
AUC	NP	<unknown>
,	,	,
a	DT	a
specificity	NN	specificity
of	IN	of
100	CD	@card@
%	NN	%
,	,	,
and	CC	and
a	DT	a
sensitivity	NN	sensitivity
of	IN	of
84.4	CD	@card@
%	NN	%
.	SENT	.
The	DT	the
combination	NN	combination
of	IN	of
IL-6	NP	<unknown>
and	CC	and
leptin	NN	<unknown>
proved	VVD	prove
to	TO	to
be	VB	be
the	DT	the
most	RBS	most
discriminatory	JJ	discriminatory
,	,	,
with	IN	with
an	DT	an
AUC	NP	<unknown>
value	NN	value
of	IN	of
0.933	CD	@card@
,	,	,
a	DT	a
specificity	NN	specificity
of	IN	of
96.7	CD	@card@
%	NN	%
,	,	,
and	CC	and
a	DT	a
sensitivity	NN	sensitivity
of	IN	of
85.7	CD	@card@
%	NN	%
.	SENT	.
The	DT	the
levels	NNS	level
of	IN	of
NO	NP	No
x	SYM	x
,	,	,
IL-6	NP	<unknown>
,	,	,
IL-18	NP	<unknown>
,	,	,
and	CC	and
leptin	NN	<unknown>
in	IN	in
plasma	NN	plasma
were	VBD	be
significantly	RB	significantly
correlated	VVN	correlate
with	IN	with
their	PP$	their
levels	NNS	level
in	IN	in
SF	NP	SF
.	SENT	.
Leptin	NN	<unknown>
levels	NNS	level
in	IN	in
both	DT	both
plasma	NN	plasma
(	(	(
p	NN	p
=	SYM	=
0.036	CD	@card@
)	)	)
and	CC	and
SF	NP	SF
(	(	(
p	NN	p
=	SYM	=
0.041	CD	@card@
)	)	)
and	CC	and
the	DT	the
synovial	JJ	synovial
IL-18	NP	<unknown>
level	NN	level
(	(	(
p	NN	p
=	SYM	=
0.045	CD	@card@
)	)	)
were	VBD	be
correlated	VVN	correlate
with	IN	with
the	DT	the
Kellgren-Lawrence	NP	<unknown>
(	(	(
KL	NP	<unknown>
)	)	)
grade	NN	grade
.	SENT	.
Early-stage	NN	early-stage
PTOA	NP	<unknown>
(	(	(
KL	NP	<unknown>
1-2	CD	@card@
)	)	)
was	VBD	be
associated	VVN	associate
with	IN	with
a	DT	a
high	JJ	high
concentration	NN	concentration
of	IN	of
IL-1β	NP	<unknown>
in	IN	in
plasma	NN	plasma
before	IN	before
and	CC	and
after	IN	after
(	(	(
OR	NP	Or
6.235	CD	@card@
,	,	,
95	CD	@card@
%	NN	%
CI	NP	<unknown>
1.362	CD	@card@
to	TO	to
28.552	CD	@card@
,	,	,
p	NN	p
=	SYM	=
0.018	CD	@card@
)	)	)
adjusting	VVG	adjust
for	IN	for
age	NN	age
,	,	,
gender	NN	gender
,	,	,
and	CC	and
BMI.Circulating	NP	<unknown>
NO	NP	No
x	SYM	x
level	NN	level
and	CC	and
a	DT	a
combination	NN	combination
of	IN	of
IL-6	NP	<unknown>
and	CC	and
leptin	NP	<unknown>
permitted	VVD	permit
the	DT	the
strongest	JJS	strong
discrimination	NN	discrimination
of	IN	of
patients	NNS	patient
with	IN	with
PTOA	NP	<unknown>
from	IN	from
controls	NNS	control
.	SENT	.
PTOA	NP	<unknown>
severity	NN	severity
was	VBD	be
correlated	VVN	correlate
with	IN	with
leptin	NN	<unknown>
levels	NNS	level
in	IN	in
plasma	NN	plasma
and	CC	and
SF	NP	SF
and	CC	and
with	IN	with
the	DT	the
synovial	JJ	synovial
IL-18	NP	<unknown>
level	NN	level
.	SENT	.
Early	NP	Early
PTOA	NP	<unknown>
was	VBD	be
associated	VVN	associate
with	IN	with
the	DT	the
circulating	VVG	circulate
level	NN	level
of	IN	of
IL-1β.III	NP	<unknown>
(	(	(
case-control	NN	<unknown>
study	NN	study
)	)	)
.	SENT	.
T.	NP	T.
Greater	NP	Greater
rheumatoid	JJ	rheumatoid
arthritis	NN	arthritis
joint	JJ	joint
improvement	NN	improvement
with	IN	with
more	JJR	more
subjects	NNS	subject
achieving	VVG	achieve
response	NN	response
across	IN	across
improvement	NN	improvement
categories	NNS	category
using	VVG	use
novel	NN	novel
versus	IN	versus
existing	VVG	exist
ultrasound	NN	ultrasound
methods	NNS	method
.	SENT	.
A.	NP	A.
We	PP	we
compared	VVD	compare
the	DT	the
change	NN	change
in	IN	in
joint	JJ	joint
inflammation	NN	inflammation
and	CC	and
the	DT	the
proportion	NN	proportion
of	IN	of
subjects	NNS	subject
achieving	VVG	achieve
threshold	NN	threshold
levels	NNS	level
of	IN	of
improvement	NN	improvement
using	VVG	use
the	DT	the
existing	JJ	existing
methods	NNS	method
employing	VVG	employ
ultrasonography	NN	ultrasonography
on	IN	on
pre-determined	JJ	pre-determined
joint	JJ	joint
sites	NNS	site
versus	CC	versus
novel	NN	novel
methods	NNS	method
.	SENT	.
These	DT	these
novel	NN	novel
methods	NNS	method
select	VVP	select
the	DT	the
most	RBS	most
affected	JJ	affected
joints	NNS	joint
based	VVN	base
on	IN	on
(	(	(
i	NP	i
)	)	)
ultrasonography-the	NN	<unknown>
Individualized-Ultrasound	NNS	<unknown>
(	(	(
IUS	NP	<unknown>
)	)	)
method	NN	method
,	,	,
or	CC	or
(	(	(
ii	NN	<unknown>
)	)	)
ultrasonography	NN	ultrasonography
and	CC	and
clinical	JJ	clinical
joint	JJ	joint
assessment-the	NN	<unknown>
individualized-Composite-Ultrasound	NNS	<unknown>
(	(	(
ICUS	NP	<unknown>
)	)	)
method	NN	method
.	SENT	.
Mean	JJ	mean
3-month	JJ	<unknown>
change	NN	change
in	IN	in
total	JJ	total
inflammation	NN	inflammation
score	NN	score
(	(	(
ΔTIS	NN	<unknown>
)	)	)
and	CC	and
95	CD	@card@
%	NN	%
CI	NP	<unknown>
was	VBD	be
computed	VVN	compute
for	IN	for
each	DT	each
method	NN	method
on	IN	on
24	CD	@card@
RA	NP	RA
subjects	NNS	subject
initiated	VVN	initiate
or	CC	or
escalated	VVN	escalate
on	IN	on
treatment	NN	treatment
.	SENT	.
Individual	JJ	individual
improvement	NN	improvement
in	IN	in
TIS	NNS	ti
per	IN	per
subject	NN	subject
,	,	,
calculated	VVN	calculate
as	IN	as
the	DT	the
3-month	JJ	<unknown>
ΔTIS	NN	<unknown>
divided	VVN	divide
by	IN	by
the	DT	the
maximum	JJ	maximum
possible	JJ	possible
TIS	NN	<unknown>
score	NN	score
expressed	VVN	express
as	IN	as
a	DT	a
percentage	NN	percentage
,	,	,
was	VBD	be
used	VVN	use
to	TO	to
obtain	VV	obtain
the	DT	the
proportion	NN	proportion
of	IN	of
subjects	NNS	subject
achieving	VVG	achieve
response	NN	response
across	IN	across
improvement	NN	improvement
categories	NNS	category
.	SENT	.
Mean	JJ	mean
3-month	JJ	<unknown>
ΔTIS	NN	<unknown>
was	VBD	be
significantly	RB	significantly
greater	JJR	great
(	(	(
p	NN	p
values	NNS	value
ranging	VVG	range
from	IN	from
0.0003	CD	@card@
to	TO	to
0.0026	CD	@card@
)	)	)
for	IN	for
novel	NN	novel
versus	CC	versus
existing	JJ	existing
methods	NNS	method
using	VVG	use
12-	CD	@card@
and	CC	and
7-joint	JJ	<unknown>
approaches	NNS	approach
.	SENT	.
Using	VVG	use
12-joint	JJ	<unknown>
approach	NN	approach
,	,	,
percentages	NNS	percentage
of	IN	of
subjects	NNS	subject
in	IN	in
improvement	NN	improvement
categories	NNS	category
≥5	NN	<unknown>
%	NN	%
,	,	,
≥10	JJ	<unknown>
%	NN	%
,	,	,
≥15	JJ	<unknown>
%	NN	%
and	CC	and
≥20	NN	<unknown>
%	NN	%
were	VBD	be
,	,	,
respectively	RB	respectively
,	,	,
50	CD	@card@
,	,	,
37.5	CD	@card@
,	,	,
12.5	CD	@card@
and	CC	and
8.3	CD	@card@
%	NN	%
for	IN	for
IUS	NP	<unknown>
;	:	;
58.3	CD	@card@
,	,	,
37.5	CD	@card@
,	,	,
12.5	CD	@card@
and	CC	and
8.3	CD	@card@
%	NN	%
for	IN	for
ICUS	NP	<unknown>
;	:	;
and	CC	and
16.7	CD	@card@
,	,	,
0	CD	@card@
,	,	,
0	CD	@card@
and	CC	and
0	CD	@card@
%	NN	%
for	IN	for
the	DT	the
existing	JJ	existing
method	NN	method
.	SENT	.
Using	VVG	use
7-joint	JJ	<unknown>
approach	NN	approach
,	,	,
the	DT	the
respective	JJ	respective
category	NN	category
percentages	NNS	percentage
were	VBD	be
62.5	CD	@card@
,	,	,
37.5	CD	@card@
,	,	,
25	CD	@card@
and	CC	and
12.5	CD	@card@
%	NN	%
for	IN	for
IUS	NP	<unknown>
;	:	;
62.5	CD	@card@
,	,	,
41.7	CD	@card@
,	,	,
16.7	CD	@card@
and	CC	and
8.3	CD	@card@
%	NN	%
for	IN	for
ICUS	NP	<unknown>
;	:	;
and	CC	and
12.5	CD	@card@
,	,	,
4.2	CD	@card@
,	,	,
4.2	CD	@card@
and	CC	and
0	CD	@card@
%	NN	%
for	IN	for
the	DT	the
existing	JJ	existing
method	NN	method
.	SENT	.
Novel	JJ	novel
ultrasound	NN	ultrasound
methods	NNS	method
are	VBP	be
more	RBR	more
likely	JJ	likely
to	TO	to
detect	VV	detect
improvement	NN	improvement
in	IN	in
joint	JJ	joint
inflammation	NN	inflammation
,	,	,
with	IN	with
more	JJR	more
subjects	NNS	subject
achieving	VVG	achieve
response	NN	response
across	IN	across
improvement	NN	improvement
categories	NNS	category
,	,	,
thereby	RB	thereby
representing	VVG	represent
a	DT	a
substantial	JJ	substantial
advantage	NN	advantage
over	IN	over
the	DT	the
existing	JJ	existing
methods	NNS	method
.	SENT	.
However	RB	however
,	,	,
this	DT	this
requires	VVZ	require
confirmation	NN	confirmation
in	IN	in
larger	JJR	large
RA	NP	RA
cohorts	NNS	cohort
.	SENT	.
T.	NP	T.
Prevalence	NP	<unknown>
of	IN	of
nasal	JJ	nasal
colonization	NN	colonization
with	IN	with
Staphylococcus	NP	<unknown>
aureus	NN	aureus
in	IN	in
patients	NNS	patient
with	IN	with
rheumatoid	JJ	rheumatoid
arthritis	NN	arthritis
.	SENT	.
A.	NP	A.
Patients	NPS	Patients
with	IN	with
rheumatoid	JJ	rheumatoid
arthritis	NN	arthritis
(	(	(
RA	NP	RA
)	)	)
and	CC	and
nasal	JJ	nasal
carriers	NNS	carrier
of	IN	of
Staphylococcus	NP	<unknown>
aureus	NN	aureus
have	VHP	have
an	DT	an
increased	VVN	increase
risk	NN	risk
of	IN	of
developing	VVG	develop
infections	NNS	infection
caused	VVN	cause
by	IN	by
S.	NP	S.
aureus	NN	aureus
.	SENT	.
Our	PP$	our
objective	NN	objective
was	VBD	be
to	TO	to
determine	VV	determine
the	DT	the
prevalence	NN	prevalence
of	IN	of
S.	NP	S.
aureus	NN	aureus
nasal	JJ	nasal
colonization	NN	colonization
in	IN	in
patients	NNS	patient
with	IN	with
RA	NP	RA
and	CC	and
its	PP$	its
relationship	NN	relationship
to	TO	to
RA	NP	RA
treatments.Two	NP	<unknown>
hundred	CD	hundred
seven	CD	seven
patients	NNS	patient
with	IN	with
RA	NP	RA
and	CC	and
37	CD	@card@
healthy	JJ	healthy
controls	NNS	control
were	VBD	be
prospectively	RB	prospectively
included	VVN	include
in	IN	in
a	DT	a
cross-sectional	JJ	cross-sectional
study	NN	study
.	SENT	.
A	DT	a
nasal	JJ	nasal
secretion	NN	secretion
sample	NN	sample
was	VBD	be
collected	VVN	collect
by	IN	by
swab	NN	swab
from	IN	from
both	DT	both
anterior	JJ	anterior
nostrils	NNS	nostril
and	CC	and
was	VBD	be
referred	VVN	refer
to	TO	to
the	DT	the
hospital	NN	hospital
's	POS	's
microbiology	NN	microbiology
department	NN	department
for	IN	for
culturing.The	NNS	<unknown>
mean	VVP	mean
age	NN	age
of	IN	of
the	DT	the
patients	NNS	patient
(	(	(
168	CD	@card@
women	NNS	woman
,	,	,
78	CD	@card@
%	NN	%
)	)	)
was	VBD	be
61	CD	@card@
±	SYM	±
12	CD	@card@
years	NNS	year
old	JJ	old
.	SENT	.
The	DT	the
mean	JJ	mean
disease	NN	disease
duration	NN	duration
was	VBD	be
13	CD	@card@
±	SYM	±
10	CD	@card@
years	NNS	year
.	SENT	.
Seventy-six	NN	<unknown>
percent	NN	percent
of	IN	of
the	DT	the
patients	NNS	patient
were	VBD	be
positive	JJ	positive
for	IN	for
rheumatoid	JJ	rheumatoid
factor	NN	factor
(	(	(
RF	NP	RF
)	)	)
,	,	,
and	CC	and
71	CD	@card@
%	NN	%
were	VBD	be
positive	JJ	positive
for	IN	for
anti-citrullinated	JJ	<unknown>
peptides	NNS	peptide
antibodies	NNS	antibody
(	(	(
ACPA	NP	<unknown>
)	)	)
.	SENT	.
Seventy	CD	seventy
percent	NN	percent
had	VHD	have
joint	JJ	joint
erosions	NNS	erosion
.	SENT	.
The	DT	the
mean	JJ	mean
DAS28	NN	<unknown>
was	VBD	be
3.1	CD	@card@
±	SYM	±
2.2	CD	@card@
.	SENT	.
S.	NP	S.
aureus	NN	aureus
nasal	NN	nasal
colonization	NN	colonization
was	VBD	be
found	VVN	find
in	IN	in
36	CD	@card@
%	NN	%
of	IN	of
the	DT	the
RA	NP	RA
patients	NNS	patient
and	CC	and
35	CD	@card@
%	NN	%
of	IN	of
the	DT	the
controls	NNS	control
.	SENT	.
Three	CD	three
patients	NNS	patient
and	CC	and
no	DT	no
controls	NNS	control
were	VBD	be
resistant	JJ	resistant
to	TO	to
oxacilin/mupirocin	NN	<unknown>
.	SENT	.
The	DT	the
patients	NNS	patient
who	WP	who
were	VBD	be
positive	JJ	positive
for	IN	for
ACPA	NP	<unknown>
had	VHD	have
a	DT	a
higher	JJR	high
prevalence	NN	prevalence
of	IN	of
S.	NP	S.
aureus	NN	aureus
colonization	NN	colonization
(	(	(
43	CD	@card@
%	NN	%
vs	NP	vs
17	CD	@card@
%	NN	%
;	:	;
p	NN	p
&lt	NN	<unknown>
;	:	;
0.05	LS	@card@
)	)	)
.	SENT	.
The	DT	the
colonization	NN	colonization
prevalence	NN	prevalence
in	IN	in
the	DT	the
patients	NNS	patient
treated	VVN	treat
with	IN	with
glucocorticoids	NNS	<unknown>
was	VBD	be
32	CD	@card@
%	NN	%
(	(	(
n	NN	n
:	:	:
133	LS	@card@
)	)	)
;	:	;
methotrexate	NN	methotrexate
and/or	CC	and/or
leflunomide	NN	<unknown>
,	,	,
37	CD	@card@
%	NN	%
(	(	(
n	NN	n
:	:	:
167	LS	@card@
)	)	)
;	:	;
anti-TNF	NN	<unknown>
agents	NNS	agent
,	,	,
46	CD	@card@
%	NN	%
(	(	(
n	NN	n
:	:	:
54	LS	@card@
)	)	)
,	,	,
p	NN	p
&lt	NN	<unknown>
;	:	;
0.05	CD	@card@
versus	IN	versus
patients	NNS	patient
not	RB	not
treated	VVN	treat
with	IN	with
anti-TNF	NN	<unknown>
agents	NNS	agent
;	:	;
rituximab	NN	<unknown>
,	,	,
22	CD	@card@
%	NN	%
(	(	(
n	NN	n
:	:	:
18	LS	@card@
)	)	)
;	:	;
tocilizumab	NN	<unknown>
,	,	,
39	CD	@card@
%	NN	%
(	(	(
n	NN	n
:	:	:
18).The	JJ	<unknown>
prevalence	NN	prevalence
of	IN	of
S.	NP	S.
aureus	NN	aureus
nasal	JJ	nasal
colonization	NN	colonization
in	IN	in
patients	NNS	patient
with	IN	with
RA	NP	RA
does	VVZ	do
not	RB	not
appear	VV	appear
to	TO	to
be	VB	be
greater	JJR	great
than	IN	than
that	DT	that
of	IN	of
the	DT	the
general	JJ	general
population	NN	population
.	SENT	.
Anti-TNF	NN	<unknown>
agents	NNS	agent
might	MD	might
confer	VV	confer
a	DT	a
higher	JJR	high
prevalence	NN	prevalence
of	IN	of
colonization	NN	colonization
.	SENT	.
T.	NP	T.
Polymorphic	NP	<unknown>
lymphoproliferative	JJ	<unknown>
disorders	NNS	disorder
in	IN	in
patients	NNS	patient
with	IN	with
rheumatoid	JJ	rheumatoid
arthritis	NN	arthritis
are	VBP	be
associated	VVN	associate
with	IN	with
a	DT	a
better	RBR	well
clinical	JJ	clinical
outcome	NN	outcome
.	SENT	.
A.	NP	A.
The	DT	the
characteristics	NNS	characteristic
of	IN	of
lymphoproliferative	JJ	<unknown>
disorders	NNS	disorder
(	(	(
LPD	NP	<unknown>
)	)	)
in	IN	in
patients	NNS	patient
with	IN	with
rheumatoid	JJ	rheumatoid
arthritis	NN	arthritis
(	(	(
RA	NP	RA
)	)	)
remain	VVP	remain
unclear	JJ	unclear
.	SENT	.
Therefore	RB	therefore
,	,	,
we	PP	we
retrospectively	RB	retrospectively
analyzed	VVD	analyze
the	DT	the
clinical	JJ	clinical
characteristics	NNS	characteristic
of	IN	of
these	DT	these
patients	NNS	patient
in	IN	in
our	PP$	our
department.Twenty	JJ	<unknown>
RA	NP	RA
patients	NNS	patient
who	WP	who
developed	VVD	develop
LPD	NP	<unknown>
between	IN	between
April	NP	April
2003	CD	@card@
and	CC	and
August	NP	August
2016	CD	@card@
in	IN	in
our	PP$	our
department	NN	department
were	VBD	be
analyzed.All	NN	<unknown>
of	IN	of
the	DT	the
RA	NP	RA
patients	NNS	patient
who	WP	who
developed	VVD	develop
LPD	NP	<unknown>
had	VHD	have
been	VBN	be
treated	VVN	treat
with	IN	with
methotrexate	NN	methotrexate
(	(	(
MTX	NP	<unknown>
)	)	)
.	SENT	.
The	DT	the
median	JJ	median
weekly	JJ	weekly
and	CC	and
total	JJ	total
dosages	NNS	dosage
of	IN	of
MTX	NP	<unknown>
were	VBD	be
6.8 mg/week	JJ	<unknown>
and	CC	and
2530 mg	JJ	<unknown>
,	,	,
respectively	RB	respectively
.	SENT	.
The	DT	the
median	JJ	median
duration	NN	duration
of	IN	of
MTX	NP	<unknown>
administration	NN	administration
was	VBD	be
eight	CD	eight
years	NNS	year
.	SENT	.
Nineteen	CD	nineteen
patients	NNS	patient
(	(	(
95	CD	@card@
%	NN	%
)	)	)
achieved	VVD	achieve
complete	JJ	complete
remission	NN	remission
(	(	(
CR	NN	CR
)	)	)
and	CC	and
15	CD	@card@
(	(	(
75	CD	@card@
%	NN	%
)	)	)
achieved	VVN	achieve
CR	NN	CR
with	IN	with
MTX	NP	<unknown>
cessation	NN	cessation
alone	RB	alone
.	SENT	.
Based	VVN	base
on	IN	on
the	DT	the
pathological	JJ	pathological
findings	NNS	finding
,	,	,
we	PP	we
divided	VVD	divide
MTX-associated	JJ	<unknown>
LPD	JJ	<unknown>
patients	NNS	patient
into	IN	into
two	CD	two
groups	NNS	group
(	(	(
n = 16	NN	<unknown>
)	)	)
;	:	;
polymorphic	JJ	polymorphic
LPD	NN	<unknown>
(	(	(
31	CD	@card@
%	NN	%
)	)	)
and	CC	and
other	JJ	other
groups	NNS	group
.	SENT	.
CR	NN	CR
with	IN	with
MTX	NP	<unknown>
cessation	NN	cessation
alone	RB	alone
was	VBD	be
achieved	VVN	achieve
in	IN	in
5	CD	@card@
(	(	(
100	CD	@card@
%	NN	%
)	)	)
and	CC	and
6	CD	@card@
(	(	(
54.5	CD	@card@
%	NN	%
)	)	)
patients	NNS	patient
in	IN	in
the	DT	the
polymorphic	JJ	polymorphic
LPD	NN	<unknown>
and	CC	and
other	JJ	other
groups	NNS	group
,	,	,
respectively	RB	respectively
(	(	(
p = .12	NN	<unknown>
)	)	)
.	SENT	.
Moreover	RB	moreover
,	,	,
the	DT	the
duration	NN	duration
from	IN	from
the	DT	the
cessation	NN	cessation
of	IN	of
MTX	NP	<unknown>
to	TO	to
CR	NN	CR
was	VBD	be
significantly	RB	significantly
shorter	JJR	short
in	IN	in
the	DT	the
polymorphic	JJ	polymorphic
LPD	JJ	<unknown>
group	NN	group
than	IN	than
in	IN	in
the	DT	the
other	JJ	other
group	NN	group
(	(	(
5.3	CD	@card@
months	NNS	month
vs	NP	vs
12.6	CD	@card@
months	NNS	month
,	,	,
p = .01	JJ	<unknown>
,	,	,
respectively).Polymorphic	JJ	<unknown>
LPD	NN	<unknown>
,	,	,
which	WDT	which
was	VBD	be
the	DT	the
most	RBS	most
frequent	JJ	frequent
pathological	JJ	pathological
diagnosis	NN	diagnosis
in	IN	in
this	DT	this
cohort	NN	cohort
,	,	,
was	VBD	be
associated	VVN	associate
with	IN	with
a	DT	a
higher	JJR	high
incidence	NN	incidence
of	IN	of
CR	NN	CR
and	CC	and
a	DT	a
significantly	RB	significantly
shorter	JJR	short
duration	NN	duration
to	TO	to
CR	NN	CR
.	SENT	.
T.	NP	T.
Concurrent	NP	<unknown>
Occurrence	NN	occurrence
of	IN	of
Primary	NP	<unknown>
Biliary	NP	<unknown>
Cirrhosis	NP	<unknown>
and	CC	and
Rheumatoid	NP	<unknown>
Arthritis	NP	<unknown>
.	SENT	.
A.	NP	A.
Primary	NP	<unknown>
biliary	JJ	biliary
cirrhosis	NN	cirrhosis
(	(	(
PBC	NP	<unknown>
)	)	)
is	VBZ	be
an	DT	an
autoimmune	JJ	autoimmune
cholestatic	JJ	<unknown>
disorder	NN	disorder
of	IN	of
the	DT	the
liver	NN	liver
.	SENT	.
A	DT	a
diagnostic	JJ	diagnostic
serum	NN	serum
marker	NN	marker
for	IN	for
PBC	NP	<unknown>
is	VBZ	be
an	DT	an
anti-mitochondrial	JJ	<unknown>
antibody	NN	antibody
.	SENT	.
Most	RBS	most
prominent	JJ	prominent
histologic	JJ	histologic
findings	NNS	finding
of	IN	of
PBC	NP	<unknown>
are	VBP	be
portal	NN	portal
inflammation	NN	inflammation
and	CC	and
destruction	NN	destruction
of	IN	of
interlobular	JJ	<unknown>
bile	NN	bile
ducts	NNS	duct
.	SENT	.
The	DT	the
PBC	NP	<unknown>
occurs	VVZ	occur
only	RB	only
in	IN	in
40	CD	@card@
to	TO	to
400	CD	@card@
individuals	NNS	individual
per	IN	per
million	CD	million
in	IN	in
the	DT	the
general	JJ	general
population	NN	population
.	SENT	.
About	RB	about
1.8	CD	@card@
-	:	-
5.6	CD	@card@
%	NN	%
of	IN	of
individuals	NNS	individual
with	IN	with
this	DT	this
rare	JJ	rare
disorder	NN	disorder
have	VHP	have
rheumatoid	JJ	rheumatoid
arthritis	NN	arthritis
(	(	(
RA	NP	RA
)	)	)
.	SENT	.
This	DT	this
case	NN	case
report	NN	report
describes	VVZ	describe
a	DT	a
56-year-old	JJ	56-year-old
female	NN	female
with	IN	with
concurrent	JJ	concurrent
rheumatoid	JJ	rheumatoid
arthritis	NN	arthritis
and	CC	and
primary	JJ	primary
biliary	JJ	biliary
cirrhosis	NN	cirrhosis
.	SENT	.
The	DT	the
patients	NNS	patient
with	IN	with
RA	NP	RA
are	VBP	be
at	IN	at
higher	JJR	high
risk	NN	risk
of	IN	of
developing	VVG	develop
PBC	NP	<unknown>
compared	VVN	compare
to	TO	to
the	DT	the
general	JJ	general
population	NN	population
.	SENT	.
Thus	RB	thus
,	,	,
abnormal	JJ	abnormal
liver	NN	liver
function	NN	function
test	NN	test
in	IN	in
the	DT	the
patients	NNS	patient
with	IN	with
RA	NP	RA
,	,	,
especially	RB	especially
in	IN	in
the	DT	the
absence	NN	absence
of	IN	of
alternative	JJ	alternative
cause	NN	cause
,	,	,
warrants	VVZ	warrant
thorough	JJ	thorough
investigation	NN	investigation
for	IN	for
PBC	NP	<unknown>
.	SENT	.
Early	JJ	early
diagnosis	NN	diagnosis
and	CC	and
treatment	NN	treatment
will	MD	will
improve	VV	improve
the	DT	the
outcome	NN	outcome
of	IN	of
patients	NNS	patient
who	WP	who
develop	VVP	develop
PBC	NP	<unknown>
.	SENT	.
T.	NP	T.
Systems	NPS	Systems
Biology	NP	<unknown>
Genetic	NP	Genetic
Approach	NP	Approach
Identifies	NP	<unknown>
Serotonin	NP	<unknown>
Pathway	NP	<unknown>
as	IN	as
a	DT	a
Possible	JJ	possible
Target	NP	Target
for	IN	for
Obstructive	NP	<unknown>
Sleep	NP	<unknown>
Apnea	NP	<unknown>
:	:	:
Results	NNS	result
from	IN	from
a	DT	a
Literature	NP	<unknown>
Search	NP	Search
Review	NP	Review
.	SENT	.
A.	NP	A.
Overall	JJ	overall
validity	NN	validity
of	IN	of
existing	VVG	exist
genetic	JJ	genetic
biomarkers	NNS	<unknown>
in	IN	in
the	DT	the
diagnosis	NN	diagnosis
of	IN	of
obstructive	JJ	obstructive
sleep	NN	sleep
apnea	NN	apnea
(	(	(
OSA	NP	<unknown>
)	)	)
remains	VVZ	remain
unclear	JJ	unclear
.	SENT	.
The	DT	the
objective	NN	objective
of	IN	of
this	DT	this
systematic	JJ	systematic
genetic	JJ	genetic
study	NN	study
is	VBZ	be
to	TO	to
identify	VV	identify
"	``	"
novel	JJ	novel
"	''	"
biomarkers	NNS	<unknown>
for	IN	for
OSA	NP	<unknown>
using	VVG	use
systems	NNS	system
biology	NN	biology
approach.Candidate	NN	<unknown>
genes	NNS	gene
for	IN	for
OSA	NP	<unknown>
were	VBD	be
extracted	VVN	extract
from	IN	from
PubMed	NP	<unknown>
,	,	,
MEDLINE	NP	<unknown>
,	,	,
and	CC	and
Embase	NP	<unknown>
search	NN	search
engines	NNS	engine
and	CC	and
DisGeNET	NN	<unknown>
database	NN	database
.	SENT	.
The	DT	the
gene	NN	gene
ontology	NN	ontology
(	(	(
GO	NP	Go
)	)	)
analyses	NNS	analysis
and	CC	and
candidate	NN	candidate
genes	NNS	gene
prioritization	NN	prioritization
were	VBD	be
performed	VVN	perform
using	VVG	use
Enrichr	NP	<unknown>
tool	NN	tool
.	SENT	.
Genes	NNS	gene
pertaining	VVG	pertain
to	TO	to
the	DT	the
top	JJ	top
10	CD	@card@
pathways	NNS	pathway
were	VBD	be
extracted	VVN	extract
and	CC	and
used	VVN	use
for	IN	for
Ingenuity	NP	<unknown>
Pathway	NP	<unknown>
Analysis.In	NP	<unknown>
total	NN	total
,	,	,
we	PP	we
have	VHP	have
identified	VVN	identify
153	CD	@card@
genes	NNS	gene
.	SENT	.
The	DT	the
top	JJ	top
10	CD	@card@
pathways	NNS	pathway
associated	VVN	associate
with	IN	with
OSA	NP	<unknown>
include	VVP	include
(	(	(
i	NP	i
)	)	)
serotonin	NN	serotonin
receptor	NN	receptor
interaction	NN	interaction
,	,	,
(	(	(
ii	NP	<unknown>
)	)	)
pathways	NNS	pathway
in	IN	in
cancer	NN	cancer
,	,	,
(	(	(
iii	NP	<unknown>
)	)	)
AGE-RAGE	NN	<unknown>
signaling	VVG	signal
in	IN	in
diabetes	NN	diabetes
,	,	,
(	(	(
iv	NP	<unknown>
)	)	)
infectious	JJ	infectious
diseases	NNS	disease
,	,	,
(	(	(
v	NN	v
)	)	)
serotonergic	JJ	<unknown>
synapse	NN	synapse
,	,	,
(	(	(
vi	NNS	<unknown>
)	)	)
inflammatory	JJ	inflammatory
bowel	NN	bowel
disease	NN	disease
,	,	,
(	(	(
vii	NNS	<unknown>
)	)	)
HIF-1	JJ	<unknown>
signaling	VVG	signal
pathway	NN	pathway
,	,	,
(	(	(
viii	NP	<unknown>
)	)	)
PI3-AKT	NP	<unknown>
signaling	VVG	signal
pathway	NN	pathway
,	,	,
(	(	(
ix	NNS	<unknown>
)	)	)
regulation	NN	regulation
lipolysis	NN	lipolysis
in	IN	in
adipocytes	NNS	<unknown>
,	,	,
and	CC	and
(	(	(
x	LS	x
)	)	)
rheumatoid	JJ	rheumatoid
arthritis	NN	arthritis
.	SENT	.
After	IN	after
removing	VVG	remove
the	DT	the
overlapping	JJ	overlapping
genes	NNS	gene
,	,	,
we	PP	we
have	VHP	have
identified	VVN	identify
23	CD	@card@
candidate	NN	candidate
genes	NNS	gene
,	,	,
out	RB	out
of	IN	of
which	WDT	which
&gt	NN	<unknown>
;	:	;
30	CD	@card@
%	NN	%
of	IN	of
the	DT	the
genes	NNS	gene
were	VBD	be
related	VVN	relate
to	TO	to
the	DT	the
genes	NNS	gene
involved	VVN	involve
in	IN	in
the	DT	the
serotonin	NN	serotonin
pathway	NN	pathway
.	SENT	.
Among	IN	among
these	DT	these
4	CD	@card@
serotonin	NN	serotonin
receptors	NNS	receptor
SLC6A4	NP	<unknown>
,	,	,
HTR2C	NP	<unknown>
,	,	,
HTR2A	NP	<unknown>
,	,	,
and	CC	and
HTR1B	NP	<unknown>
were	VBD	be
strongly	RB	strongly
associated	VVN	associate
with	IN	with
OSA.This	NP	<unknown>
preliminary	JJ	preliminary
report	NN	report
identifies	VVZ	identify
several	JJ	several
potential	JJ	potential
candidate	NN	candidate
genes	NNS	gene
associated	VVN	associate
with	IN	with
OSA	NP	<unknown>
and	CC	and
also	RB	also
describes	VVZ	describe
the	DT	the
possible	JJ	possible
regulatory	JJ	regulatory
mechanisms	NNS	mechanism
.	SENT	.
